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Abstract 
 
Dionne Renee Glast 
G Protein-coupled Receptors:  A Function in Breast Carcinoma Metastasis and Insight Into 
the Regulation of Agonist-promoted Internalization 
(Under the direction of Dr. Robert A. Nicholas) 
 
 This dissertation is comprised of two projects investigating the function of GPCR 
signaling and regulation in cancer and/or cardiovascular physiology.  The first study 
delineated the functional importance of PAR2 in breast cancer migration and invasion by 
using small interfering RNAs (siRNAs) to deplete highly invasive breast cancer cells of 
endogenous PAR2 protein. Our findings strongly suggest that PAR2 is critical for MDA-
MB-231 and BT549 breast cancer cell migration and invasion towards NIH-3T3 fibroblast 
conditioned medium.  We also examined the importance of PAR2 in mediating factors VIIa 
and Xa responses.  We showed that MDA-MB-231 cells depleted of PAR2 exhibit a marked 
inhibition of VIIa and Xa signaling to phosphoinositide hydrolysis and ERK1/2 activation, 
whereas signaling by VIIa and Xa remained intact in PAR1 deficient cells. Factors VIIa and 
Xa-induced cellular migration was also impaired in MDA-MB-231 cells deficient in PAR2 
but not in cells lacking PAR1. The results from these studies reveal the novel findings that 
PAR2 has a critical role in breast cancer cell migration and invasion and functions as the 
endogenous receptor for coagulant proteases VIIa and Xa in these cells.  
 For the second study, we investigated the regulation of agonist-promoted P2Y1 
receptor internalization in Madin-Darby Canine Kidney cells.  Our studies revealed that 
Ser336 within a highly conserved S336RAT339 sequence regulates agonist-promoted P2Y1 
 iii
 internalization.  We showed that mutation of Ser336 to Ala resulted in internalization rates 
faster than wild type receptors in response to agonist.  Agonist-promoted [32P]phosphate 
incorporation studies indicated that increased phosphorylation was not the cause of enhanced 
internalization.  Arrestin-GFP mobilization and internalization studies in arrestin2- and 
arrestin3-null mouse embryonic fibroblasts revealed that both wild type and mutant receptors 
required arrestins to undergo agonist-promoted internalization. We propose a model in which 
Ser336 regulates arrestin binding to an active conformation of the receptor. This model 
predicts that mutation of Ser336 to Ala increases the rate of internalization as a result of 
increased arrestin binding. These studies increase our understanding of the internalization 
and regulation of the P2Y1 receptor, a GPCR critical in regulation of various processes 
including ion and water transport across epithelia, smooth muscle relaxation, and platelet 
activation.   
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Chapter 1 
General Introduction 
1.1. G protein-coupled receptors 
 Maintaining homeostasis in any living multicellular organism requires cells to 
sense their external environment, communicate with each other, and respond rapidly to 
extracellular signals.  These extracellular signals that regulate many important 
physiological processes are regulated via multiple cell-surface signaling receptors, 
including G protein-coupled receptors. 
 G protein-coupled receptors (GPCRs) were initially discovered through studies 
examining the dose-dependent activity of neurotransmitters, peptide hormones, and 
natural and synthetic drugs in animal models, isolated organs, and tissues.  The targets for 
most of these molecules turned out to be GPCRs and ion channels.  GPCRs are expressed 
in a wide variety of tissues and represent the largest and most versatile group of cell 
surface receptors.  This seven transmembrane (7TM) superfamily (~800 functional 
genes) responds to a diverse range of stimuli, such as light, odor, taste, pheromones, and 
neurotransmitters.  More than thirty percent of all drugs currently used target GPCRs 1.  
Theses drugs have therapeutic actions across a wide range of human diseases, including 
neurodegenerative, psychiatric and immune disorders, cardiovascular, gastrointestinal, 
renal, and pulmonary diseases, pain, and cancer 1-2 (TABLE 1.1).    
 GPCRs generally fall into one of three main receptor families:  rhodopsin-like 
family A, secretin-like family B, or metabotropic glutamate/pheromone-like family C3.  
Sequences within each family generally share over twenty-five percent sequence 
homology in the seven transmembrane core regions.  The rhodopsin-like family A is the 
largest subgroup and contains olfactory, small-molecule/peptide hormones, protease-
activated, and purinergic GPCRs.  Family A GPCRs are characterized by several highly 
conserved amino acids in the seven transmembrane bundle.  In addition, there is usually a 
disulfide bridge linking extracellular loops E1 and E2.  Most family A receptors have at 
least one cysteine residue in the intracellular carboxyl-terminal tail that is palmitoylated, 
thus promoting its interaction with the membrane.   
 Secretin-like family B GPCRs include approximately 50 receptors for peptides 
such as secretin, calcitonin, and parathyroid hormone.  These receptors are characterized 
by a relatively long amino-terminus and contain a network of three conserved disulfide 
bridges defining a globular domain structure.  The family B receptors show a number of 
conserved proline residues within the seven transmembrane segments that are thought to 
be essential for the conformational shape of the receptors.  Secretin-like receptors 
preferentially couple to the Gαs protein (over Gαi, Gα12, and Gαq) to activate adenylyl 
cyclase 4. 
 In addition to the metabotropic glutamate (mGluR) receptors, family C GPCRs 
also include receptors for γ-aminobutyric acid type B (GABAB), Ca2+ and several amino 
acids.  Of the 17 members of family C receptors, the majority are characterized by having 
both a large amino-terminus and carboxyl-terminal tail, a disulfide bridge connecting the 
first and second extracellular loops, and a very short, well-conserved third intracellular 
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loop.  A number of the highly conserved residues of class A GPCRs are also conserved in 
class C GPCRs, consistent with class A and class C receptors sharing a common ancestor.  
The ligand-binding site, which is located in the amino-terminus, is composed of the 
venus flytrap module (VFTM) that shares sequence homology with bacterial periplasmic 
amino acid-binding proteins.  In all class C GPCRs, except the GABAB receptor, a 
cysteine-rich domain (CRD) consisting of nine conserved cysteine residues links the 
VFTM to the seven transmembrane domain5. 
 
1.2. Classical G protein-coupled receptor signaling 
1.2.1. Heterotrimeric GTP-binding proteins (G proteins)  
 GPCRs couple to heterotrimeric GTP-binding proteins (G proteins) to regulate a 
variety of cell responses.  G proteins are composed of three protein subunits-α, β, and γ, 
with the latter two subunits forming an obligate dimer.  Some G proteins are ubiquitously 
expressed while others are expressed in selective tissues.  There are 16 mammalian Gα 
subunits that are categorized into four families based upon primary structure and 
signaling properties:  Gαs, Gαi/o, Gαq/11, and Gα12/13.  Gβγ dimers are combinations of five 
isoforms of the Gβ subunit and thirteen isoforms of the Gγ subunit. 
 In the basal state, the inactive GDP-bound Gα subunit is complexed with a Gβγ 
dimer and a GPCR.  Receptor activation leads to the exchange of GDP for GTP on the α 
subunit, which promotes dissociation of the G protein complex into the GTP-bound Gα 
subunit and the Gβγ dimer, both of which have the capacity to signal individually to 
downstream effectors.  Thus, activated receptors function as guanine nucleotide-
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exchange factors (GEFs) that stimulate the dissociation of GDP from Gα and the binding 
of GTP from the cytosol. 
 Hydrolysis of GTP to GDP by the intrinsic GTPase activity in Gα subunits leads 
to signal termination and re-association of the heterotrimeric complex.  GTPase-
activating proteins (GAPs) increase the rate of GTP hydrolysis.  Regulators of G protein 
signaling (RGS) proteins are GAPs that enhance the intrinsic GTPase activity of the Gα 
subunit.  There are ~25 RGS proteins encoded in the human genome and these proteins 
are critical in regulating G protein-mediated responses. 
 The dissociation of the heterotrimeric G protein activates its two components in 
different ways.  GTP binding causes a conformational change that affects the association 
of the Gα subunit with the Gβγ complex and allows the Gα subunit to interact with 
downstream target proteins.  The Gβγ complex does not change, but does interact with 
downstream effectors as well.   
 
1.2.2. G protein-coupled receptor signal transduction 
 Signal transduction is achieved through the coupling of G proteins to various 
secondary pathways involving ion channels, adenylyl cyclases, and phospholipases to 
regulate a broad range of physiological processes, including gene transcription, 
chemotaxis, and ion channel opening.  This coupling results in production of second 
messengers.   
 Gαs activates adenylyl cyclase to stimulate intracellular cyclic AMP (cAMP) 
levels.  Gαi/o inhibits adenylyl cyclase and triggers other signaling cascades.  Gαq/11 
activates phospholipase Cβ (PLCβ) resulting in the hydrolysis of phosphatidylinositol-
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4,5-bisphosphate (PIP2) to inositol-1,4,5-triphosphate (IP3) and diacylglycerol (DAG).  
DAG increases the activity of protein kinase C (PKC) and IP3 triggers the release of Ca2+ 
ions from intracellular stores.  Gα12/13 activates Rho family proteins.  Gβγ dimers signal 
to a large number of effectors including ion channels, phospholipases, phosphoinositide 
kinases, and the ras/raf/ERK (extracellular signal-regulated kinase) pathways.   
 
1.3. Regulation of G protein-coupled receptor signaling 
 
 Following GPCR activation, the receptor must be desensitized in order to 
terminate receptor signaling.  Receptor desensitization and signal termination usually 
occur as a consequence of three different mechanisms:  1) uncoupling and desensitization 
of the receptor from G proteins in response to receptor phosphorylation and arrestin 
binding, 2) receptor internalization to intracellular compartments, and 3) downregulation 
of the total amount of receptor due to lysosomal sorting and subsequent degradation of 
pre-existing receptors.  The time frames over these mechanisms range from seconds 
(phosphorylation) to minutes (internalization) to hours (downregulation).  A number of 
factors, including receptor structure and cellular environment, regulate the extent of 
receptor desensitization which varies from complete signal termination (visual and 
olfactory receptors)6 to attenuation of agonist potency and maximal responsiveness 
(β2AR)7-8. 
 
1.3.1. G protein-coupled receptor desensitization by uncoupling the G protein in 
response to phosphorylation  
 Ligand binding to GPCRs and activation of signaling pathways leads to covalent 
modification of the receptor through phosphorylation by intracellular kinases.  In general, 
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second messenger-dependent protein kinases [i.e. cAMP-dependent protein kinase (PKA) 
and protein kinase C (PKC)] and G protein receptor kinases (GRKs) phosphorylate 
GPCRs on serine and theronine residues in both the intracellular loops and carboxyl-
terminal tail9-11.  As their name indicates, second messenger-dependent protein kinases 
are activated by second messengers (see below), which results in phosphorylation of both 
the activated receptor and other receptors that are not in the activated state. In contrast, 
GRKs specifically phosphorylate only activated receptors. Arrestin binds to 
phosphorylated receptors and promotes the uncoupling of G proteins from the receptor to 
terminate signaling7,12.   
 
1.3.1a. Multiple sites of G protein-coupled receptor phosphorylation 
 
 Mutagenesis13-20 and antibody studies21 on a wide range of receptors demonstrate 
that GPCRs are phosphorylated at multiple sites.  Early studies on rhodopsin showed that 
phosphorylation is sequential or hierarchical, which is also believed to be true for 
nonvisual GPCRs22.  For example, the chemokine N-formyl peptide C5a receptor is 
basally phosphorylated by an unknown kinase, which primes the receptor for agonist-
induced phosphorylation18,23-24.  The δ-opioid receptor is phosphorylated primarily at 
Ser363 in the carboxyl tail, and a S363A mutation inhibits phosphorylation at other sites 
on the carboxyl tail24.  Additionally, in vitro phosphorylation experiments of the M3-
muscarinic receptor by protein kinase casein kinase 2 (CK2) revealed that mutating one 
consensus site resulted in the loss of a number of phosphoylation events on the third 
intracellular loop.  These data suggest that the kinase phosphorylates the receptor at 
multiple sites in the region and that the phosphorylation is hierarchical25.  Finally, basal 
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phosphorylation of the bradykinin B2 receptor at Ser346 on the carboxyl tail is followed 
by multiple phosphorylation that was both time-dependent and ligand-concentration 
dependent.  This phosphorylation pattern is due to multiple kinases that include GRKs, 
PKC, and at least one unidentified protein kinase26. 
 
1.3.1b. Second messenger-dependent kinases 
 The second messenger-dependent kinases, PKA and PKC, are activated in 
response to GPCR-stimulated increases in intracellular second messengers such as cyclic 
AMP (cAMP), Ca2+, and diacylglycerol and participate in GPCR signaling by 
phosphorylating downstream effector proteins.  Additionally, second messenger-
dependent kinases also phosphorylate GPCRs at consensus sites within the intraceullar 
loop and carboxyl tail to facilitate desensitization in a feedback mechanism.  For 
example, upon activation of the β2AR, PKA is activated and subsequently phosphorylates 
the receptor in at least one of two PKA consensus sites13,27-28. 
 
1.3.1c. G protein receptor kinases 
 The GRK family consists of seven family members (GRK 1-7) that share 
significant sequence homology and structure.  Each GRK contains a central catalytic 
domain, an amino-terminal domain that contains an RGS-like domain and is important 
for substrate recognition, and a carboxy-terminal domain that is important for targeting to 
the plasma membrane.  Most GRKs are localized in the cytosol in the basal state, and 
following receptor activation they translocate to the plasma membrane to phosphorylate 
GPCRs at serine and threonine residues in the third intracellular loops or carboxy-
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terminal tails.  In addition to promoting desensitization, the functional role of GPCR 
phosphorylation by GRKs is to promote arrestin binding and signaling. 
 
1.3.1d. Other receptor kinases 
 The studies mentioned above (1.3.1a) involving M3-muscarinic receptor 
phosphorylation by CK2 and bradykinin B2 receptor phosphorylation by an unidentified 
kinase indicate a role for the involvement of multiple protein kinases in GPCR 
phosphorylation.  In addition to CK2, whose cellular effect is to regulate Jun-kinase 
signaling upon GPCR phosphorylation, casein kinase 1 (CK1) has been shown to 
phosphorylate the M3-muscarinic receptor to regulate ERK1/2 signaling29-30.  Evidence 
for a role of other protein kinases is also supported by the fact that some GPCRs, 
including the β2-adrenergic and insulin receptors, are tyrosine phophorylated31-34.  
Phosphorylation of the β2-adrenergic receptor by the Akt/PKB (protein kinase B) protein 
regulates agonist-induced internalization and cellular migration.  Interestingly, Akt/PKB-
induced phosphorylation is regulated by insulin receptor activation of PI-3 kinase.  
Glucose metabolism is controlled by insulin, which stimulates glycogen synthesis, 
glucose uptake and lipid storage.  The actions of insulin are amplified by the insulin 
receptor-mediated tyrosine phosphorylation of the β2-adrenergic receptor and subsequent 
internalization.   
 
1.3.1e. Role of phosphorylation in arrestin interaction with G protein-coupled 
receptors 
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 GPCRs can also function as scaffolding proteins that interact with a variety of 
signaling molecules; these interactions are often influenced by the conformation of the 
receptor.  The general dogma is that agonist binding results in a change in the positions of 
transmembrane α-helices III and VI, resulting in a re-orientation of the third intracellular 
loop in a manner that facilitates G-protein coupling35.  This conformational change is also 
presumed to unmask potential phosporylation sites on the intracellular domains of 
GPCRs36.  The synergistic effects of conformational changes and posttranslational 
modification allow the receptor to interact with proteins that were previously 
inaccessible.  Additionally, a conformation change of the receptor may lead to the 
conformational change in interacting proteins and subsequent signal transduction.  
Arrestins are a prime example of GPCR-interacting proteins that interact with receptors 
in a phosphorylation-dependent manner. 
 There are four family members in the arrestin family.  Arrestin1 and arrestin4 
(visual arrestins) are expressed solely in rod and cone photoreceptor cells and interact 
with phosphorylated rhodopsin and cone opsins to terminate phototransduction37.  
Arrestin2 and arrestin3 (nonvisual arrestins) are also known as β-arrestin1 and β-
arrestin2.  These proteins are expressed in a variety of tissues and can regulate hundreds 
of activated and phosphorylated GPCRs38.  Generally, the concave surface of arrestins 
recognize and bind with high affinity to multiple phosphorylated serine and threonine 
sites on the receptor to inhibit G-protein coupling and desensitize the receptor39.   
 Structural studies of arrestin have revealed amino and carboxyl termini composed 
of antiparellel β-sheets that are linked by an unusual 12-residue polar core39.  The basal 
conformation of arrestin is maintained by a network of intramolecular interactions 
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between charged residues buried within the polar core38.  The amino terminus of arrestin 
binds to various GPCR intracellular sequences, whereas positively charged polar core 
interacts with receptor-associated phosphates.  Upon binding to activated and 
phosphorylated GPCRs, arrestins undergo a conformational change induced by 
engagement of receptor-associated phosphates with the polar core.  Binding is followed 
by exposure of the arrestin C-terminal domain, which interacts with components of the 
endocytic machinery, including the clathrin heavy-chain and the β2-adaptin subunit of 
AP2, and thereby facilitates GPCR internalization39. 
 The molecular mechanism of receptor/arrestin binding appears to be conserved 
between visual and nonvisual arrestins.  However, there is a range of receptor/arrestin 
affinities.  Class A receptors have a relatively low affinity for arrestins and the complex 
dissociates during the trafficking of the receptor to intracellular compartments.  Class B 
receptors have a significantly high affinity for arrestins and the complex remains intact 
during the trafficking of the receptor to intracellular compartments following agonist 
stimulation40-41.  
 It is also clear that phosphorylation is not a requirement for arrestin binding for all 
receptors.  Phosphorylation-deficient mutants (substance P and leukotriene B4 receptors) 
still maintain the ability to interact with arrestins42-43.  In addition, activated oxrexin-144 
and protease-activated receptor-2 mutants45 that have mutations in putative 
phosphorylation sites can still bind arrestins.  Thus, it is possible that arrestins interact 
with multiple sites on the receptor and that these multiple interactions are sufficieint to 
form a stable complex in the absence of phosphorylation. 
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1.3.2. G protein-coupled receptor internalization 
 Agonist-stimulated GPCR internalization into intracellular compartments of the 
cell is an important mechanism in regulating signal magnitude and duration.  Receptor 
internalization has been intensively and extensively investigated over the past several 
years and much is now understood regarding the molecular mechanisms involved in 
regulating internalization.  Studies have identified GPCR domains involved in receptor 
internalization, adaptor proteins, and multiple endocytic mechanisms.  The molecular 
mechanisms of GPCR internalization and intracellular trafficking were initially 
generalized from data on β2-adrenergic receptor internalization46-47 (Figure 1.1).  
However, recent studies investigating other GPCRs in a number of different cell types 
have revealed various patterns in GPCR internalization as well as intracellular trafficking.  
Studies have also revealed that the rates of internalization vary for each receptor48, further 
supporting the idea that GPCR internalization can be mediated by multiple endocytic 
mechanisms.  In addition, the different rates of internalization between different GPCRs 
may be reflective of the binding of different endocytic adaptor proteins to facilitate 
internalization. 
 Following internalization, the receptor signaling response is regulated by 
intracellular sorting.  Internalized receptors are typically sorted to recycling or lysosomal 
pathways, trafficking routes that produce opposite effects on signal duration and 
magnitude.  Endocytic trafficking to lysosomes is a major pathway by which many 
GPCRs are downregulated after agonist stimulation49, while the recycling pathway 
promotes rapid recovery (resensitization) of cellular responsiveness.  Alternatively, some 
 11
GPCR-arrestin complexes remain intact and continue to signal, or initiate new signaling 
pathways from the endosomal membrane45. 
 Receptor-mediated endocytosis involves multiple steps: receptors bind to 
complementary adaptor proteins, accumulate in coated pits, and enter the cell as a 
receptor-adaptor protein complex within vesicles that bud off the plasma membrane.  
This process is a selective concentrating mechanism that increases the efficiency of 
internalization of ligands.  Most G protein-coupled receptors internalize into cells via 
clathrin-coated vesicles.  Clathrin-mediated endocytosis has been extensively studied and 
much information is available on the molecular mechanisms of clathrin-mediated 
endocytosis as well as on the adaptor proteins that regulate internalization.  More 
recently, it has become clear that not all GPCRs internalize in a clathrin-dependent 
manner, but the molecular mechanisms are not fully understood and there are many 
adaptor proteins yet to be discovered. 
 
1.3.2a. Clathrin-mediated endocytosis 
 Clathrin-mediated endocytosis is the major route for intergral membrane proteins 
and cell-surface receptors, including GPCRs.  An endocytic-coated vesicle begins with 
recruitment of clathrin, adaptor, and endocytic accessory proteins to plasma membrane 
regions enriched in phosphatidylinositol (4,5)-bisphosphate (PIP2), where they form 
patches ranging in diameter from 10 nm to more than 500 nm.  Electron microscopy has 
provided images of polygonal clathrin networks at various stages of invagination, which 
culminate in almost completely closed polyhedral structures that surround coated 
membrane buds50.  These images led to the accepted budding model in which the 
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internalization process starts with predominantly flat hexagonal lattices that turn into 
curved ones.  Release of the clathrin-coated vesicle from the plasma membrane is 
mediated by the large GTPase dynamin.  Eventually, vesicles encased in a clathrin 
network separate from the plasma membrane by a process referred to as fission.  Before 
fusion with endosomes, clathrin and adaptors are released from the vesicular membrane.  
The now soluble coat proteins can engage in a fresh round of coated vesicles. 
 The function of clathrin adaptor proteins is to enrich specific cargo within a 
forming vesicle51.  The adaptor protein complex-2 (AP2), the most abundant adaptor 
protein found in clathrin-coated vesicles at the plasma membrane, recognizes short linear 
tyrosine- and/or dileucine-based cytoplasmic sequences of cargo proteins52.  Increasing 
evidence suggests that monomeric clathrin adaptors that bind clathrin and PIP2 co-operate 
with AP2 to recruit cargo and promote clathrin-dependent endocytosis.  Recent work has 
also identified an α-helical motif in several monomeric adaptor proteins, including 
arrestins, autosomal recessive hypercholesterolemia (ARH) and epsins, that bind the β2-
subunit of AP2 with high affinity53.  Clathrin adaptors interact with short linear 
sequences, in addition to recognizing phosphorylated and ubiquitinated cargo (Figure 
1.4).  Clathrin adaptors themselves are also modified by phosphorylation and 
ubiquitination, suggesting that clathrin adaptor activity is tightly regulated.   
 The first monomeric adaptor proteins shown to function in clathrin-mediated 
endocytosis were the nonvisual arrestins.  Nonvisual arrestins interact with clathrin and 
AP2 and facilitate internalization of activated and phosphorylated GPCRs.  A second 
group of monomeric clathrin adaptor proteins include epsins, clathrin assembly lymphoid 
myeloid leukemia protein (CALM)/AP180 (AP180 is a neuronal ortholog of CALM, 
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Huntington-interacting protein-1 (HIP1), and HIP1-related protein (HIP1R).  These 
proteins contain an N-terminal PIP2-binding domain [epsin N-terminal homology 
(ENTH)/AP180 N-terminal homology (ANTH) domain] and interact with clathrin and 
AP2.  In addition, epsin harbors three ubiquitin-binding domains (UBDs), binds eps15 
and eps15-related protein (eps15R), which also contain UBDs, and recruits ubiquitinated 
cargo to clathrin-coated pits.  Both CALM/AP180 and HIP/HIPR lack UBDs and how 
they function in cargo recruitment is unknown.  HIP1 and HIP1R dimerize via their 
coiled-coil regions and HIP1R binds directly to F-actin linking the actin cytoskeleton to 
the endocytic machinery.  
 A third group of monomeric clathrin adaptors include disabled-2 (Dab2), ARH, 
and numb.  Members of this group bind AP2, some interact with clathrin, and all contain 
a phosphotyrosine-binding (PTB) domain that recognizes FXNNPXY motifs, although 
tyrosine phosphorylation is not required for binding. Very few studies examining the 
function of other clathrin adaptors in GPCR endocytosis exist, with the exception of 
arrestins.  A summary of clathrin adaptor proteins and their interactions is provided 
(Figure 1.2) 
 
1.3.2a.i. G protein-coupled receptor kinases 
 Depending on the GPCR studied, GRK-mediated phosphorylation is not an 
absolute requirement for internalization.  For example, β2AR mutants lacking sites for 
both second messenger-dependent protein kinase- and GRK-mediated receptor 
phosphorylation internalized comparably to the wildtype receptor13,54.  In contrast, a 
protease-activated receptor-1 mutant lacking all possible carboxyl tail phosphorylation 
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sites failed to internalize55.  GRK-mediated phosphorylation appears to have a role in 
GPCR internalization by stabilizing a conformation required to promote interaction of the 
receptor with adaptor proteins that directly promote receptor internalization.  In fact, 
GRK-phosphorylation increases the binding affinity of GPCRs for non-visual arrestins, 
which in addition to uncoupling the receptor from heterotrimeric G proteins, act as an 
endocytic adaptor protein to target GPCRs for clathrin-mediated internalization8-9.  Thus, 
the β2AR mutant that lacks sites for GRK-mediated phosphorylation must be able to 
interact with an endocytic adaptor protein in the absence of phosphorylation. 
 
1.3.2a.ii. Arrestins 
 The ubiquitously expressed arrestin2 and arrestin3, also known as β-arrestin1 and 
β-arrestin2, are best known for their regulatory role in desensitization (by uncoupling 
GPCRs from the heterotrimeric G-protein complex) and internalization.  The mechanism 
by which arrestins promote GPCR endocytosis is best characterized for the β2AR56.  
Activation of the β2AR causes translocation of arrestins to the plasma membrane where 
the receptor preferentially binds arrestin3 rather than arrestin2.  The activated β2AR-
arrestin complex redistrbutes to clathrin-coated pits and arrestin dissociates upon receptor 
internalization.  Arrestin interaction with clathrin and AP2 is essential for agonist-
induced β2AR internalization.  The endocytic activity of arrestin is controlled by both 
phosphorylation and ubiquitination.  Arrestins are basally phosphorylated and 
dephosphorylated upon recruitment to the plasma membrane.  Dephosphorylation of 
arrestins is required for agonist-promoted β2AR internalization.   
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 In addition to phosphorylation, the ubiquitination status of arrestin is important 
for its endocytic activity.  Arrestins interact with the E3 ubiquitin ligase mouse double 
minute-2 (Mdm2), which specifically ubiquitinates arrestins bound to activated β2AR57.  
Ubiquitination of arrestin is essential for β2AR internalization.   
 The first reports of arrestin-independent GPCR internalization used dominant-
negative arrestin and dynamin mutants.  Using these mutants, the m1, m2, m3, and m4 
muscarinic acetylcholine receptors58-59, prostacyclin receptor60, and 5-HT2A serotonin 
receptor61 were shown to internalize through an arrestin-independent, dynamin-dependent 
pathway.  More definitive evidence for an arrestin-independent mechanism for GPCR 
endocytosis came from the use of mouse embryo fibroblasts (MEFs) derived from 
arrestin2 and arrestin3 knockout mouse mice62.  Both constitutive and agonist-induced 
internalization of PAR1 were shown to proceed through an arrestin-independent but 
clathrin- and dynamin-dependent pathway in MEFs lacking endogenous arrestins63.  
Subsequent studies using arrestin-null MEFs demonstrated arrestin-independent 
internalization of the N-formyl peptide receptor64, the human viral chemokine receptor 
US2865 and the urotensin receptor66.  These studies provide strong evidence that alternate 
clathrin adaptors function in GPCR endocytosis. 
 In addition to GPCRs, arrestins also regulate endocytosis of other cell-surface 
receptors and integral membrane proteins including the insulin-like growth factor-1 
receptor, type III transforming growth factor-β receptor, low-density lipoprotein (LDL) 
receptor, the Na+/H+ exchanger 5 transporter and most recently vascular/endotheilial 
(VE)-cadherin67.  In some cases, arrestins facilitate endocytosis by binding to 
phosphorylated serine/threonine residues in the cytoplasmic regions of these cargo 
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proteins.  Thus, like other clathrin adaptors, arrestins are capable of regulating 
endocytosis of diverse cargo. 
 
1.3.2.aiii. Adaptor protein complex-2 
 The finding that several GPCRs internalize independent of arrestins suggests that 
other clathrin adaptors function as critical regulators of mammalian GPCR endocytosis.  
One such critical clathrin adaptor is the adaptor protein complex-2.  AP2 was the first 
clathrin adaptor identified and is still the key protein in the model of clathrin-dependent 
internalization.  The heterotetrameric AP2 complex is composed of α (100 kD), β2 (100 
kD), µ2 (50 kD), and σ2 (17 kD) subunits.  Three subunits directly function in clathrin 
coat assembly.  The amino terminus of the α2 subunit of AP2 binds to PIP2 to position 
AP2 on the plasma membrane68-69, while the β2 subunit has a flexible hinge the contains 
a clathrin-binding sequence (clathrin box) that binds to the terminal domain of the 
clathrin heavy chain promoting lattice assembly70-71.  Cargo proteins bind to directly to 
AP2 through its µ2 subunit72 while the primary role of the σ2 subunit is structural69. 
 Transmembrane proteins require an internalization signal for rapid endocytosis.  
AP2 is able to recruit cargo through the µ2 subunit interactions with the tyrosine-based 
motif, YXXΦ (where X is any amino acid and Φ is a bulky hydrophobic residue).  In 
addition, α2/σ2 subunits and possibly the β2 subunit recognizes acidic dileucine motifs 
([DE]XXXL[LI]) on cargo proteins73.  The endocytic activity of AP2 is regulated by µ2 
subunit phosphorylation mediated by the AP2-associated kinase, AAK1, which enhances 
µ2 affinity for YYXΦ motifs74. 
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 AP-2 is known to mediate endocytosis of a variety of cell-surface receptors and 
integral membrane proteins, and a recent study demonstrated that AP2 functions directly 
in GPCR endocytosis.  AP2, and not arrestin2 or -3, is required for constitutive 
internalization of PAR1 in a clathrin- and dynamin-dependent manner. Constitutive 
PAR1 internalization creates an intracellular pool of naïve receptor that replenishes the 
cell surface after thrombin exposure and is required for rapid cellular resensitization 
independent of de novo receptor synthesis.  The µ2 subunit of AP2 was shown to directly 
bind to a tyrosine-based motif (YXXL) in the cytoplasmic tail of PAR1 using Surface 
Plasmon Resonance.  In addition, expression of a PAR1 tyrosine mutant or depletion of 
AP2 by siRNA led to significant inhibition of PAR1 constitutive internalization, loss of 
intracellular, uncleaved PAR1, and failure of endothelial cells and other cell types to 
resensitize to thrombin signaling.  Interestingly, internalization of agonist-activated 
PAR1 is neither dependent on arrestins nor AP2, suggesting that constitutive and agonist-
induced internalization requires distinct endocytic machinery75. 
 Several GPCRs contain tyrosine- and dileucine-based motifs conforming to 
canonical and non-canonical AP2-recognition motifs in their cytoplasmic tails75, 
suggesting that AP2 might function in trafficking of other GPCRs.  The thromboxane β 
receptor (TPβ) cytoplasmic tail contains a YXXXΦ and displays arrestin-independent 
constitutive internalization, but the role of AP2 has not been tested76. The CXCR2 
chemokine receptor in which both cytoplasmic tail dileucine motifs were mutated bound 
arrestin but failed to interact with AP2 to undergo agonist-induced internalization77.  The 
β2AR and CXCR4 also contain a cytoplasmic tail dileucine motif that appears to function 
in receptor endocytosis.  Mutation of the β2AR cytoplasmic tail dileucine motif affects 
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agonist-induced endocytosis78, but the affects on arrestin and AP2 binding is unknown.  
Interestingly, agonist-induced CXCR4 internalization is dependent on serine residues and 
an adjacent dileucine motif in some cell types79, yet in other cell lines, the serine and 
dileucine endocytic signals are required for PKC-mediated internalization but not for 
agonist-induced internalization80-81. 
 
1.3.2a.iv. Disabled-2, autosomal recessive hypercholesterolemia, and numb 
 Numb, Dab2, and ARH are clathrin adaptor proteins that contain a 
phosphotyrosine-binding domain (PTB) domain that recognizes FXNPXY motifs in the 
cytosolic sequences of cargo.  Outside of the PTB domain, the carboxy terminus of Dab2, 
ARH, and numb are predicted to be disordered, and like arrestins, contain adjacent 
clathrin box and/or AP2 appendage-binding sequences82-85.  The Xenopus ARH 
orthologue requires these features to drive the internalization of the vitellogenin receptor, 
an FXNPXY-containing member of the LDLR family86.  In addition, in Drosophila, there 
is strong genetic evidence for a numb-AP2 internalization in endocytosis87.  These data 
suggest that PTB adaptor proteins can bind cargo, PIP2, and clathrin in addition to AP2. 
 ARH and Dab2 have well-established functions in LDL receptor internalization, 
whereas numb has been shown to regulate endocytosis of a variety of integral membrane 
proteins including EGFR and notch.  A recent study shows that numb is phosphorylated 
and redistributed to the plasma membrane following activation of the neurokinin-
1/substance P receptor88.  However, numb is not essential for receptor internalization and 
a role for Dab2 and ARH has not been demonstrated. 
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1.3.2a.v.  Epsin superfamily 
 An alternate group of adaptors include epsin 1, CALM/AP180, HIP1, and 
HIP1R89.  These proteins contain an N-terminal PIP2-binding ENTH/ANTH domain90 
and all bind to and colocalize with AP2 and clathrin.  Ubiquitination is the primary 
internalization signal in S. cerevisiae, and the yeast epsins, Ent1p and Ent2p, use 
ubiquitin-interaction motifs (UIMs) to promote rapid internalization91. Mutant alleles of 
Liquid facets, the Drosophila epsin, that disrupt ubiquitin prevent internalization of the 
transmembrane Notch ligand Delta in compound eye progenitors and consequently, 
severely malformed eyes develop92.  Mammalian epsin UIMs may act similarly; 
however, interpretation of many studies is complex as a variety of proteins are 
ubiquitinated upon EGFR activation.  
 Studies suggest that the C. elegans AP180 orthologue, UNC-11, may participate 
in the sorting of synaptobrevin.  Genetic disruption of the UNC-11 gene leads to selective 
mis-sorting of the v-SNARE protein at the presynaptic plasma membrane93.  In addition, 
GluR1-containing AMPA receptor endocytosis is defective in neurons from HIP1-/- 
mice94.  Currently, the molecular basis for AP180 and HIP1 cargo recognition is 
unknown.  Both proteins lack UIMs, but the similarity between the ANTH and VHS 
(another cargo recognition module) domains suggest that ubiquitination may function in 
cargo selection and internalization. 
 
1.3.2a.vi. Actin 
 A regulatory role for actin in yeast S. cerevisiae endocytosis has been clearly 
established; however its function in mammalian internalization is less clear.  Yeast and 
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mammalian endocytosis not only differ in their requirement for actin but also for 
dynamin.  Although dynamin is essential for release of clathrin-coated pits in mammalian 
cells, it does not appear to have a direct role in yeast endocytosis.  Recently, the 
dynamics of actin, clathrin, and GPCR recruitment to endocytic sites in yeast were 
examined using total internal reflection fluorescence (TIRF) microscopy in living cells95.  
These studies used a combination of fluorescently tagged Ste2, a GPCR for the mating α-
factor, pharmacological inhibitors, and mutant yeast strains lacking critical actin 
components to establish more clearly an essential role for actin cytoskeleton in Ste2 
endocytosis.  In budding yeast, actin appears to function mainly in plasma membrane 
invagination, constriction, and scission.  
 In contract to the yeast Ste2 receptor, the role of actin in mammalian GPCR 
endocytosis is less clear.  In mammalian cells, actin appears at the plasma membrane in a 
transient burst just prior to clathrin-coated pit scission in living cells.  However, its 
precise function in endocytosis is not well understood96.  Given that many GPCRs 
interact directly or indirectly with a variety of actin-binding proteins such as EBP50, 
spinophilin, filaminA/ABP-280, cofilin, and spectrin, endocytosis of at least some 
GPCRs is likely to be regulated in an actin-dependent manner.   
 
1.3.2a.vii. Ubiquitination 
 Although arrestins play a major role in desensitization and internalization of many 
mammalian GPCRs, their function is not evolutionarily conserved.  The yeast S. 
cerevisiae do not express arrestins, but the protein Vps26 has a structural fold similar to 
arrestins97.  Both biochemical and genetic studies indicate that Vps26 exists as part of the 
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retromer complex that functions in retrograde trafficking between endosomes and the 
trans Golgi network and Vps26 is unlikely to function in endocytosis.  Instead of 
arrestins, internalization of yeast GPCRs requires ubiquitin, a small 76-amino acid 
polypeptide that functions as an internalization endocytic-sorting signal98.  Protein 
ubiquitination is mediated by the sequential action of a ubiquitin-activating enzyme (E1), 
ubiquitin-conjugating enzyme (E2), and ubiquitin ligase (E3).  E3 ligases are diverse and 
mediate substrate specificity. 
 Hicke et al. demonstrated an essential role for ubiquitination in endocytosis of 
Ste2 using yeast strains that lack specific ubiquitin-modifying enzymes and Ste2 
ubiquitin mutants or chimeras98.  Terrell et al. also showed that mono-ubiquintination is 
necessary and sufficient for both constitutive and agonist-induced internalization99.  
Although mono-ubiquitination is sufficient for endocytosis, attachment of short ubiquitin 
chains to lysine-63 of an adjacent ubiquitin facilitates endocytosis of many 
transmembrane proteins100.  In addition, phosphorylation of activated Ste2 facilitates 
ubiquitination and promotes internalization101.  A role for ubiquitination in endocytosis of 
Ste3, a GPCR for the mating a-factor, also has been established102. A recent study 
showed that ubiquitination differentially regulates clathrin-dependent internalization of 
PAR1103, although the clathrin adaptor that mediates agonist-induced internalization of 
ubiquitinated PAR1 has yet to be identified. In contrast, several studies have suggested 
that mammalian GPCR ubiquitination is essential for lysosomal sorting but not for 
receptor internalizaition57,104.  
 Several adaptor proteins, including epsin and eps15, contain ubiquitin-binding 
domains (UBDs) that recognize ubiquitinated cargo and facilitate internalization through 
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clathrin-coated pits.  The NPF domains of epsin binds the epsin homology (EH) motifs in 
eps15 and these proteins likely function cooperatively to recruit ubiquitinated cargo to 
clathrin-coated pits. 
 Similar to arrestins, the endocytic function of epsin is regulated by 
phosphorylation and ubiquitination105.  Epsin is basally phosphorylated and ubiquitinated 
and an influx of Ca2+ initiates rapid dephosphorylation106.  De-phosphorylated epsin is 
then de-ubiquinated by the de-ubiquitinating enzyme, FAM/USP9X.  In yeast, the epsin 
homologs, Ent1 and Ent2, as well as the eps15 homolog, Ede1, have been shown to 
regulate Ste2 internalization91.  In mammalian cells, epsin has been shown to regulate 
endocytosis of epidermal growth factor (EGFR) and the epithelial sodium channel107-109, 
but its function in mammalian GPCR internalization is unknown.  Given that several 
GPCRs are ubiquitinated and internalize independent of arrestins, it is plausible that 
certain receptors will use an epsin and/or eps15-dependent mechanism for internalization.  
In addition, many GPCRs couple to G proteins that activate phospholipase Cβ (PLCβ), 
resulting in PIP2 hydrolysis and Ca2+ mobilization raising the possibility that activated 
GPCRs may regulate epsin activity, thus allowing it to function as a clathrin adaptor for 
mammalian GPCRS. 
 
1.3.2.b. Clathrin-independent endocytosis 
 In addition to clathrin-coated pits and vesicles, there are other, less well-
understood mechanisms by which cells can form vesicles.  One of these pathways 
initiates at caveolae, originally recognized by their ability to transport molecules across 
endothelial cells.  Caveolae are present in the plasma membrane of most cell types, and in 
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some cell types are seen as deeply invaginated 50-80 nm flasks in electron micrographs.  
Caveolae are thought to form from lipid rafts, which are patches of plasma membrane 
that are rich in cholesterol, glycosphinglipids, and GPI-anchored membrane proteins.  
The major structural protein in caveolae is the integral membrane protein, caveolin. 
 The large GTPase dynamin was shown to be involved in a clathrin-independent 
pathway that is mediated by caveolae.  Since vesicle scission at the plasma membrane is 
required for internalization, it was assumed that dynamin might have a role in all forms of 
endocytosis.  However, it was later discovered that some clathrin-independent endocytic 
pathways are dynamin-independent, based on studies utilizing exogenous expression of 
mutant dynamin isoforms110 or from analysis of organisms that are homozygous for 
mutant dynamin111.  Thus, clathrin-independent internalization pathways can be 
categorized based on their dynamin dependence. 
 Little is known about how cargo is selected for the clathrin-independent 
endocytosis.  In contrast to clathrin-dependent endocytosis, in which specific adaptor 
molecules have been identified that recruit cargo to coated pits, no such well-defined 
adaptors for clathrin-independent endocytosis have been identified.  One potential 
mechanism that has been considered is sorting based on the association of cargo with 
microdomains at the plasma membrane.  It should be noted, however, that the association 
of cargo with detergent-resistant membranes (DRMs) does not guarantee subsequent 
internalization by a clathrin-independent mechanism112-114. 
 It recently has been suggested that ubiquitination could have a role in determining 
whether a protein is internalized via a clathrin-dependent or –independent mechanism.  
Ubiquitination of some receptor tyrosine kinases, e.g. the epidermal growth factor (EGF) 
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receptor, is mediated by c-Cbl, an E3 ubiquitin ligase.  Ubiquitin ligases are enzymes that 
function downstream of or in combination with an ubiquitin-conjugating enzyme (E2) to 
attach ubiquitin molecules to a target protein, marking the protein for subsequent 
recognition by ubiquitin-binding domains.  Although EGF receptors have been found to 
be internalized through both clathrin-dependent and –independent pathways, it was 
recently suggested that ubiquitination might be used to sequester EGF receptors into 
clathrin-independent routes, despite the fact that they also have clathrin-pit localization 
signals.  For example, high concentrations of EGF promote ubiquitination of EGF 
receptors, association with DRMs, and endocytosis has a cholesterol-sensitive clathrin-
independent mechanism, possibly by caveolae113.   
 Mechanistically, it has been difficult to elucidate the sequestration of cargo in 
caveolae.  Some data suggest that EGF receptors are guided into the caveolar pathway by 
three ubiquitin interacting motif (UIM)-containing proteins:  EPS15, epsin, and EPS15R.  
However, all three proteins are somewhat redundant in their function because a strong 
inhibitory phenotype is only observed in triple small interfering RNA (siRNA) knock-
down studies113.  These studies were controversial based on the established function of 
EPS15, epsin, and EPS15R in classic clathrin-dependent internalization. 
 Clathrin-independent internalization has also been described for GPCRs, 
including the endothelian A  (ETAR) and endothelian B (ETBR) receptors, adenosine 
A1, β1-adrenergic, bradykinin B2, and chemokine receptors115.  To characterize the 
various endocytic routes used by different receptors, several pharmacological and 
biochemical tools have been used.  These include blockers that do not discriminate 
between clathrin-dependent or caveolae-mediated internalization (ex. hypertonic sucrose, 
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low temperature, concanavalin-A, and dominate-negative mutants of dynamin) as well as 
with inhibitors believed to selectively inhibit clathrin-coated vesicle endocytosis (e.g. 
monodansylcadaverine, chlorpromazine, as well as dominant-negative mutants of Eps15) 
or caveolae-mediated endocytosis (e.g. filipin and nystatin)115-118.  Although these 
approaches have been useful, interpretation of the data were sometimes difficult because 
the tools were an indirect measurement. 
 The above discussion illustrates the importance of developing new tools that 
allow direct assessment of the molecular steps involved in endocytosis of specific 
GPCRs.  Hamdan et al. took advantage of the fact that, for internalization, arrestin 
binding to the β2-adaptin subunit of the clathrin AP-2 is needed for arrestin-mediated 
targeting of GPCRs to clathrin-coated pits.  They designed a bioluminescence resonance 
energy transfer (BRET)-based assay that allows real-time monitoring of the interaction 
between arrestins and β2-adaptin as a biosensor for arrestin-promoted clathrin-mediated 
endocytosis.  BRET is a non-fluorescence energy transfer that occurs between the energy 
donor Renilla luciferase (Rluc) and variants of the green fluorescent proteins as energy 
acceptors only when the two proteins are within 100 Å from one another and situated in 
favorable orientation, making it an attractive assay for studying both inducible and 
constitutive protein-protein interactions.   
 BRET was assessed between arrestin-Rluc and β2-adaptin-EYFP in response to 
the activation of 12 different GPCRs, including V1aR, β2AR, ETAR, ETBR, V1P1R, 
V2R, AT1aR, EP4R, C5aR, CCR5, B2R, and M2R, previously suggested to internalize 
via different endocytic routes.  The data showed that some of the GPCRs previously 
suggested to internalize via a clathrin-independent pathway were capable of promoting 
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arrestin interaction with AP2.  Thus, these receptors internalize via an arrestin- and 
clathrin-dependent mechanism.   
The ETAR and ETBR receptors are capable of recruiting arrestins but were 
shown to internalize via caveolae.  These receptors, however, did not promote arrestin 
interaction with β2-adaptin, suggesting an arrestin-dependent, but clathrin-independent 
endocytic pathway119.  In addition to providing a new tool to dissect the molecular events 
involved in GPCR endocytosis, the BRET-based arrestin/β2 adaptin interaction assay can 
also be used to detect constitutive receptor internalization and to quantify receptor 
activation in a pharmacologically relevant manner. 
 
1.3.3. G protein-coupled receptor down-regulation 
 G protein-coupled receptor desensitization is the downregulation of total receptor 
levels following prolonged agonist treatment.  Endocytic sorting to lysosomes is the 
major pathway by which most GPCRs and other cell surface receptors, including receptor 
tyrosine kinases, are down-regulated following activation49,120-122.  When agonist is 
present for an extended period of time, receptors are sorted to lysosomes and 
subsequently degraded (Figure 1.1).  For example, the β2AR predominantly recycles after 
initial agonist-induced internalization, but can undergo significant down-regulation 
following prolonged exposure to agonist.  Such behavior in receptor regulation is thought 
to be physiologically important and may contribute to the loss of drug potency or 
effectiveness observed over time in clinical settings123-124.   
   
1.4.  G protein-coupled receptors as therapeutic targets 
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 GPCRs represent the largest family of cell-surface molecules involved in signal 
transduction by a large margin, accounting for >2% of the total genes encoded by the 
human genome.  These receptors control key physiological functions such as 
neurotransmission, hormone and enzyme release from endocrine and exocrine glands, 
and immune responses, and pathological conditions such as thrombosis, atherosclerosis, 
and inflammation.  Their dysfunction contributes to some of the most prevalent human 
diseases, including cardiovascular diseases and cancer, as reflected by the fact that 
GPCRs are targets (directly or indirectly) of 50-60% of all current therapeutic agents.   
 
1.4.1.   G protein-coupled receptor signaling and thrombosis 
 Cardiovascular diseases are major causes of death in the developed world, and are 
becoming an increasing burden in a number of developing countries.  In the United 
States, cardiovascular disease, including high blood pressure, coronary heart disease, 
stroke, and heart failure, claimed almost one in three deaths in 2004 (American Heart 
Association, 2008).  Thrombosis, which is formation of a blood clot within the blood 
vessel that results in occlusion of blood flow, is a major problem that triggers both 
myocardial infarction and stroke.  Thrombosis is the result of inappropriate triggering of 
a normal protective homeostatic mechanism, haemostasis, the function of which is to 
prevent excessive blood loss following injury.   
 Platelets form the first line of defense, triggering haemostasis upon encountering 
damaged tissue.  When tissue is damaged, it triggers the release of prothrombotic factors, 
such as oxidized lipids, and exposure of collagen, which trigger thrombosis.  Thus, 
therapeutic targeting of receptors in platelets that mediate thrombosis is an effective 
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means to prevent and treat cardiovascular disease.  The regulation of platelet function, 
and therefore haemostasis and thrombosis, is a tightly regulated balance between 
activation and inhibitory mechanisms that control platelet activation upon exposure to 
damaged tissues, yet enables platelets to remain quiescent in the undamaged circulation.  
Characterization of these mechanisms, including agonists, receptors, and signaling 
pathways involved, is essential for the understanding of platelet function in health and 
disease and for the development of more effective anti-platelet therapies.  Thrombin and 
purinergic signaling, mediated by G protein-coupled protease-activated (PAR) and P2Y 
receptors, respectively, are important regulators of platelet biology (Figure 1.3).  
Chapter three in this dissertation investigates the mechanisms of regulation of P2Y1 
receptor internalization.  These data could ultimately provide insight into the 
mechanism of platelet function and thrombosis regulation. 
 
1.4.2.  G protein-coupled receptor expression and cancer 
 Emerging experimental and clinical data indicate that GPCRs have a crucial role 
in cancer progression and metastasis.  Malignant cells can hijack the normal 
physiological functions of GPCRs to proliferate autonomously, evade immune detection, 
increase their nutrient and oxygen supply, invade their surrounding tissues and 
disseminate to other organs.  Activating mutations of G proteins and GPCRs drive the 
unregulated growth of some endocrine tumors and constitutively active GPCRs are even 
expressed from the genomes of human oncogenic DNA-viruses. 
 GPCRs are the target of key inflammatory mediators, therefore providing a 
probable link between chronic inflammation and cancer.  In addition, GPCRs have a 
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central role in tumor-induced angiogenesis and tumor metastasis via GPCR-guided 
migration of cancer cells to their target organs.  Ultimately, aberrant overexpression of 
GPCRs and their autocrine and paracrine activation by agonists released from tumor or 
stromal cells represents the most frequent tactic used by tumor cells to stimulate GPCRs 
and their signaling networks.  Among such overexpressed GPCRs are protease-activated 
receptors.  The specific roles of protease-activated receptor 1 (PAR1) and protease-
activated receptor 2 (PAR2) in migration and invasion of carcinoma cells will be 
examined in chapter two.   
 
1.5. Coagulant proteases and protease-activated receptors 
1.5.1. Coagulation and cellular signaling 
 Blood coagulation is part of an important host defense mechanism termed 
haemostasis, which is the termination of blood loss from a damaged vessel.  Upon vessel 
injury, platelets adhere to macromolecules in the subendotheilal tissues and then 
aggregate to form the primary haemostatic plug.  Platelets stimulate local activation of 
plasma coagulation factors, leading to generation of a fibrin clot that reinforces the 
platelet aggregate.  Later, as wound healing occurs, the platelet aggregate and fibrin clot 
are broken down.  Mechanisms that restrict formation of platelet aggregation and fibrin 
clots to sites of injury are necessary to maintain the fluidity of the blood. 
 The coagulation cascade has two pathways, the intrinsic or contact activation 
pathway and the extrinsic or tissue factor pathway that lead to fibrin formation (Figure 
1.4).  The pathways are a series of reactions, in which a zymogen (inactive enzyme 
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precursor) of a serine protease and its glycoprotein co-factor are activated to catalyze the 
next step in the reaction cascade, ultimately resulting in cross-linked fibrin.   
 The primary pathway for the initiation of blood coagulation is the tissue factor 
pathway.  Its main role is to generate a “thrombin burst” where thrombin, the major 
effector of the coagulation cascade, is released.  The extrinsic pathway is initiated 
following damage to the blood vessel when the cell surface integral membrane protein 
tissue factor comes in contact with plasma.  Tissue factor is expressed by epithelial cells, 
macrophages, and other cell types that normally are not in contact with blood and 
circulating factors.  Tissue factor binds to factor VII and activates it by forming the TF-
FVIIa complex. TF-VIIa in turn activates factor X which converts prothrombin to 
thrombin. The contact activation pathway begins when plasma protein factor XII 
becomes activated (XIIa) once it comes in contact with collagen beneath the 
endothelium.  FXIIa converts FXI into FXIa.  Factor XIa activated FIX, which with its 
co-factor FVIIIa activated FX to FXa. 
 Thrombin has a variety of functions.  Its primary role is the conversion of 
fibrinogen to fibrin, the building block of a haemostatic plug.  In addition, it activates 
Factors VII and V and their inhibitor protein C (in the presence of thrombomodulin), as 
well as Factor XIII, which forms covalent bonds that crosslink the fibrin polymers that 
form from activated monomers.  Following activation by the contact factor or tissue 
factor pathways, the coagulation cascade is maintained in a prothrombic state by the 
continued activation of FVIII and FIX to form the ternase complex, until it is down-
regulated by the anticoagulant pathways. In addition to acting on blood proteins, 
thrombin also activates protease-activated receptors. 
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 1.5.2. Protease-activated receptors 
 The coagulant protease thrombin mediates a variety of cellular responses 
important for haemostasis and thrombosis, as well as atherogenesis, restenosis, and 
embryonic development.  Thrombin is a potent activator of platelets and endothelial cells, 
and is a mitogen for fibroblasts and vascular smooth muscle cells.  Thrombin elicits its 
actions through the activation of at least three protease-activated G protein-coupled 
receptors:  PAR1, PAR3, and PAR4.  A fourth protease-activated receptor, PAR2, is 
activated by multiple trypsin-like serine proteases, including factor VIIa-Xa (tissue-
factor) complex (Table 1.2). 
 
1.5.2a. PAR1 
 PAR1 is expressed in a wide variety of cell types including platelets, endothelium, 
epithelium, fibroblasts, myocytes, neurons, and astrocytes.  Formerly known as the 
thrombin receptor, PAR1 was cloned by two laboratories by employing the strategy of 
expressing RNA from thrombin-responsive cells of humans and hamsters in oocytes from 
Xenopus125-126.  cDNA libraries from thrombin-responsive megakaryocyte-like HEL and 
Dami cells were synthesized and transcribed in vitro.  The resulting cRNA was injected 
into Xenopus oocytes and screened for thrombin-induced calcium responses.  Clones 
were identified that encoded a protein of 425 residues with seven hydrophobic domains 
typical of a GPCR.  The deduced sequence of PAR1 contains an amino-terminal signal 
sequence, an extracellular amino-terminal domain of 75 residues, and two sites on the 
extracellular amino-terminus that are important for thrombin binding and activation.  The 
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binding site is a negatively-charged hirudin-like sequence (DKYEPFWEDEE) that 
interacts with the recognition site of thrombin (Table 1.2).   
 The mechanism by which thrombin activates PAR1 has been investigated in 
detail.  The interaction between PAR1 and thrombin is believed to induce a 
conformational change that facilitates the binding of the catalytic site of thrombin and 
subsequent cleavage after 41Arg (LDPR41 ↓ S42FLLRN, where ↓ denotes cleavage).  After 
cleavage, a new tethered ligand, S42FLLRN, is exposed and binds to and activates the 
receptor, resulting in signal transduction.  Several observations support this mechanism 
of activation.  Mutation of the cleavage site prevents thrombin cleavage and signaling, 
supporting the importance of this site for PAR1 activation126.  A synthetic peptide that 
mimics the tethered-ligand domain (S42FLLRNPNDKYEPF) directly interacts with 
PAR1 without the requirement for hydrolysis by thrombin126, and peptides as short as six 
residues (S42FLLRN) are also fully active127.  In addition to thrombin, several serine 
proteases, including coagulation proteases factor VIIa and factor Xa, metalloproteases, 
and plasmin are also capable of cleaving and activating PAR1128-129. 
 
1.5.2b. PAR2 
 PAR2 was identified by screening a mouse genomic library with degenerate 
primers designed from the second and sixth transmembrane domains of the bovine 
neurokinin 2 receptor130-131.  A clone was found that encodes a protein of 395 residues 
with the typical characteristics of a GPCR and with ~30% sequence homology to PAR1.  
The extracellular amino terminus of 46 resides contains a putative trypsin cleavage site 
(SKGR34↓S35LIGKV).  Similar observations indicated that trypsin cleavage of PAR2 at 
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R34↓S35LIGKV reveals the amino-terminal tethered ligand SLIGKV130-132.  For example, 
mutation of the trypsin site inhibits trypsin cleavage and activation of PAR2, and 
synthetic peptides corresponding to the tethered ligand domain activate PAR2 in the 
absence of receptor cleavage. 
 PAR2 is expressed in a variety of cell types including human endothelial, smooth 
muscle, leukocytes, fibroblasts, and epithelial cells and appears to regulate a broad range 
of normal physiological responses, including chemotaxis, cell growth, mitogenesis, and 
angiogenesis133-137.  PAR2 has also been implicated in various pathological responses 
including tissue repair, inflammation, and pain134,138-139.  In addition to trypsin and 
tryptase, the tissue factor-factor Xa- factor VIIa complex can activate PAR2135 (Table 2). 
 
1.5.2c.  PAR3 
 The observation that platelets from PAR1-deficient mice still responded to 
thrombin suggested the existence of additional receptors for thrombin140.  PAR3 was 
cloned by using degenerate primers designed from conserved domains of PAR1 and 
PAR2 to screen a cDNA library from rat platelets141.  Human and mouse forms of PAR3 
were cloned and found to have ~28% sequence homology to human PAR1 and PAR2.  
The thrombin cleavage site for PAR3 within the extracellular amino terminus is at 
LPIK38↓T39FRGAP.  Cleavage by thrombin exposes a new tethered ligand (T39FRGAP) 
that is thought to interact intramolecularly with the receptor.  However, in contrast to 
PAR1, PAR2, and PAR4, synthetic peptides corresponding to the putative tethered ligand 
do not activate PAR3.  Another unexpected observation was that mouse PAR3 did not 
signal when expressed in the absence of other PARs.  Expressing mouse PAR4 alone in 
 34
COS-7 cells resulted in thrombin-promoted phosphoinositide hydrolysis; however, co-
expression of mouse PAR4 with mouse PAR3 decreased the EC50 for thrombin-
stimulated phosphoinositide hydrolysis by 10-fold142.  Thus, it is assumed that mouse 
PAR3 acts as a cofactor for thrombin cleavage and activation of mouse PAR4.  Thrombin 
is thought to remain transiently tethered to PAR3 via the hirudin-like sequence to cleave 
and activate PAR4 in trans.  PAR3 expression is observed on endothelial cells, myocytes, 
and astrocytes (Table 1.2). 
 
1.5.2d.  PAR4 
 PAR4, a 385-amino acid protein with a potential cleavage site for thrombin and 
trypsin in the extracellular amino-terminal domain, was found through searching 
expressed sequence tag (EST) libraries143-144.  Thrombin and trypsin cleave PAR4 at 
PAPR47↓G48YPGQV, and peptides corresponding to the tethered-ligand domain 
GYPGQV can directly activate PAR4 (Table 1.2).  PAR4 is ~33% homologous to the 
other human PARs, but has distinct differences in the amino- and carboxyl-terminal 
domains.    Interestingly, PAR4 does not have a hirudin-like thrombin-binding domain 
like PAR1 and PAR3143-144.  Consequently, activation of PAR4 requires ~50-fold higher 
thrombin concentrations than that required to activate PAR1.  The agonist peptide 
concentration required for PAR4 activation is also substantially higher than those for 
PAR1 and PAR2.   
 In addition, PAR4 displays a slower and more sustained signaling response 
compared to PAR1145.  In transfected fibroblasts, activated PAR4 promoted substantially 
higher phosphoinositide hydrolysis per activated receptor than activated PAR1 and was 
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shut off more slowly.  For PAR1, agonist-induced shutoff and internalization depends 
upon phosphorylation of the carboxyl-tail.  PAR4 phosphorylation is undetectable, 
however, and agonist-induced internalization was much slower than that observed for 
PAR1145. 
 
1.5.3. Regulation of protease-activated receptor signaling 
 PAR1, the prototype of this family, couples to multiple G-protein subtypes 
including Gq, Gi, Go, and G12/13 to elicit a variety of cellular responses, including 
cytoskeletal changes, adhesion, migration, gene transcription, and proliferation.  Because 
proteolytic activation creates a tethered ligand that cannot diffuse away, the mechanisms 
that contribute to termination of receptor signaling are critical in determining the 
magnitude and duration of thrombin responses in cells. 
 Despite the irreversible proteolytic mechanism of PAR1 activation, signaling by 
the receptor to G protein activation is rapidly terminated by a phosphorylation- and 
arrestin-dependent mechanism.  Activated PAR1 is then internalized, sorted directly to 
lysosomes, and rapidly degraded49.  Thus, in contrast to most GPCRs, internalization and 
lysosomal sorting of activated PAR1 is required for termination of signaling.  PAR1 
utilizes a clathrin- and dynamin-dependent pathway for internalization based on 
observations that activated PAR1 was rapidly recruited to clathrin-coated pits and 
internalization was blocked by dominant-negative dynamin and clathrin hub mutants in 
both fibroblasts and HeLa cells55.  In striking contrast to most GPCRs, activated PAR1 
internalizes independent of arrestins63. 
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1.6. Role of PARs in physiology 
1.6.1. Embryonic development 
 Protease-activated receptors have an important function in embryonic 
development through their contribution to normal blood vessel development.  At mid-
gestation, approximately half of PAR1-deficient embryos die with pericardial edema, 
bleeding, and delayed maturation of yolk sack vasculature140,146.  It is difficult to attribute 
the bleeding and death of PAR1-deficient embryos to a platelet function defect because 
PAR1 does not function in mouse platelets and mice that lack platelets or platelet 
responses to thrombin develop normally.  PAR1 is expressed most abundantly in 
endocardial and endothelial cells at midgestation, and the endothelial-specific Tie2 
promoter drives PAR1 expression to prevent the death of PAR1-deficient embryos146.  
Thus, it seems as though PAR1 expression and signaling in endothelial cells is required 
for blood vessel development.  Interestingly, knockout of several coagulation factors 
causes abnormal vascular development147-150, suggesting that coagulant proteases signal 
through PAR1 in the embryo. 
 
1.6.2. Cardiovascular system 
 Endothelium-dependent relaxation or contraction, depending on the type of blood 
vessel, is regulated by PAR1.  In endothelial cells, PAR1 also controls angiogenesis and 
alters the expression of multiple genes, including chemokines, cytokines, and cell 
adhesion molecules.  In smooth muscle cells, activation of PAR1 regulates contraction, 
hypertrophy, production of the extracellular matrix (ECM), cellular migration, and 
proliferation. 
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 In addition to PAR1, other protease-activated receptors have a role in regulating 
the vasculature.  PAR2 also controls relaxation and angiogenesis in endothelial cells and 
in smooth muscle cells regulate the contraction, cell migration, proliferation, production 
of ECM, and hypertrophy.  PAR4, along with PAR3 as a cofactor, has been reported to 
induce nitric oxide (NO) production in endothelial cells, and endothelium-dependent 
relaxation151.  The role of PAR4 in smooth muscle cell regulation has yet to be defined. 
 
1.6.3. Platelet activation 
 PAR knockout mice and blocking antibodies have been invaluable in 
understanding the function of protease-activated receptors in platelet activation by 
thrombin.  Thrombin is generated at the sites of vascular injury when tissue factor is 
exposed to plasma coagulant proteases.  Platelet activation by thrombin induces shape 
change, release of ADP and thromboxane A2 (TxA2), and integrin-mediated aggregation.  
ADP and TxA2 further act on platelets to create a positive feedback loop to amplify 
platelet activation.  Activated platelets also provide a surface for assembly of the ternase 
and prothrombinase complexes to produce more thrombin. 
 In platelets, PAR1 couples to several G proteins to regulate signaling pathways 
important for activation.  PAR1 coupling to Gαq is required for platelet shape change, 
secretion and aggregation, Gα13 contributes to shape change and Gαz/i synergize signaling 
by other platelet agonists.  PAR4 also couples to Gαq and possibly Gα13, but not to Gαi in 
fibroblasts.  The importance of differential G protein coupling between PAR1 and PAR4 
has yet to be determined for platelet function. 
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 Interestingly, there are species-specific differences in platelet PAR expression.  
PAR1 and PAR4 mediated thrombin signaling in human platelets whereas PAR3 and 
PAR4 are functional receptors in mouse platelets.  In human platelets, low thrombin 
concentration is sufficient to induce secretion and aggregation through PAR1 activation.  
In contrast, high thrombin concentrations activate PAR4 in the absence of PAR1, 
suggesting redundancy in this important system.  Additionally, it is possible that PAR4, 
which lacks a thrombin-binding hirudin-like sequence, is activated by proteases other 
than thrombin.  Platelet activation by cathepsin G, a granzyme released by activated 
neturophils, is mediated by PAR4; however the importance of this phenomenon in vivo is 
unknown. 
 
1.7. Pathology of PARs and therapeutics 
 
1.7.1. Hemostasis and thrombosis 
 Thrombosis is a pathologic process in which a platelet aggregate and/or a fibrin 
clot forms in the lumen of an intact blood vessel or in a chamber of the heart.  If 
thrombosis occurs in an artery, the tissue supplied by the artery may undergo ischemic 
necrosis (i.e., myocardial infarction due to thrombosis of a coronary artery).  If 
thrombosis occurs in a vein, the tissues drained by the vein may become inflamed.  
Thrombosis of a deep vein in a lower extremity may be complicated by pulmonary 
embolism, in which all or a portion of the thrombus breaks loose, is carried in the 
bloodstream through the vena cava and the right side of the heart, and becomes lodged in 
a pulmonary artery.  Massive pulmonary embolism can cause hypoxemia, shock, and 
death. 
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 Thrombin-mediated activation of platelets and endothelial cells via PAR1 plays 
an important function in regulating haemostasis.  Therefore, developing therapies aimed 
at inhibiting thrombin function have garnered much attention.  However, data from 
mouse studies suggest that thrombin is absolutely necessary for haemostasis, and in man 
a relatively narrow therapeutic index with these agents is observed142-143.  A significant 
portion of prothrombin-deficient mice die at midgestation due to cardiovascular collapse 
and the surviving mice die from uncontrollable bleeding.  In addition, clinical studies in 
human patients show that inhibiting thrombin increases bleeding risks, suggesting that 
thrombin is not a viable therapeutic target. 
 Studies in platelets from PAR4-/- mice, which are not activated by thrombin, 
suggest that PARs are viable therapeutic targets143.  However, because of the species 
difference in PAR expression in platelets, antagonizing PARs in humans for anti-
coagulant therapy is more complicated than in mice.  In humans, it may be necessary to 
antagonize both PAR1 and PAR4 for therapeutics aimed at inhibiting thrombin activation 
of platelets, since both receptors mediate thrombin-stimulated platelet activation.  
Additionally, thrombin triggers fibrin formation and protein C activation in addition to 
activating PARs on platelets.  Thus, PAR antagonists have the potential to block 
thrombin-mediated platelet activation without affecting these other functions of thrombin. 
 
1.7.2. Cancer 
 A function for PAR1 in breast carcinoma cell invasion is suggested by increased 
PAR1 mRNA and protein expression detected in highly invasive breast carcinoma cell 
lines and in infiltrating ductal carcinomas of breast tissue specimens.  In contrast, PAR1 
 40
expression is minimal or absent in noninvasive cell lines, premalignant atypical 
hyperplasia, and normal breast epithelial tissue specimens.  Importantly, the addition of 
thrombin further increases invasiveness of certain breast carcinoma cells.  Antisense 
inhibition of PAR1 expression reduces invasion in vitro in response to thrombin and 
fibroblast conditioned medium152. 
 In a study quantifying PAR1 protein expression in human mammary carcinoma 
cell lines, thrombin-induced invasive potential was determined by examining the ability 
of cells to invade through a reconstituted basement membrane in vitro.  Increased PAR1 
protein expression correlated with the degree of cellular invasiveness exhibited by the 
various breast carcinoma cell lines152.  These findings strongly suggest that activation of 
PAR1 is required for thrombin-mediated breast carcinoma cell invasion, and raise many 
questions regarding the molecular basis for these effects. 
 In highly invasive breast carcinoma cells, activated PAR1 fails to efficiently 
down-regulate, whereas the receptor is rapidly degraded in normal noninvasive human 
mammary epithelial cells (HMECs) that ectopically overexpress PAR1.  The failure of 
activated PAR1 to be efficiently down-regulated was due to a decrease in PAR1 
internalization and increase of recycling in breast carcinoma cells compared to 
HMECs152.  Thus, activated PAR1 is not sorted to lysosomes and degraded in invasive 
breast carcinoma cells and could explain the increased expression of PAR1 protein.  As a 
result of aberrant sorting to lysosomes, proteolytically activated PAR1 caused sustained 
activation of phosphoinositide hydrolysis and extracelluar signal-related kinase (ERK 
1/2) signaling in highly invasive cells.  ERK1/2 not only promotes cell cycle progression, 
but also contributes to cellular transformation, migration, and survival.  No gene 
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mutations were detected in the endogenous PAR1 coding sequence and the mechanism(s) 
responsible for abnormal PAR1 trafficking or signaling in invasive breast carcinoma cells 
is not known.   
 In addition to thrombin, which has a known role in tumor metastasis, it is possible 
that other coagulation proteases, upstream of thrombin generation, contribute to cellular 
responses in the tumor microenvironment via activation of PAR1 and PAR2.  Tissue 
factor is highly overexpressed in invasive carcinoma cells and has been shown to 
promote cellular signaling, tumor growth, and angiogenesis.  Tissue factor also plays an 
important role in metastasis by generating active coagulant proteases factor VIIa and Xa.  
 
1.8 Purinergic signaling and receptors 
 
1.8.1. Purinergic signaling 
 The concept of purinergic signaling was introduced in 1929 by Drury and Szent-
Györgyi when ATP was discovered as an extracellular signaling molecule in the heart 
and blood vessels.  However, ATP was known as an intracellular energy source and the 
notion that such a ubiquitous molecule would be an extracellular messenger was 
considered unlikely by many.  Evidence that ATP was a neurotransmitter in 
nonadrenergic, noncholinergic (NANC) nerves supplying the gut was presented in 1970, 
and in 1972 the word "purinergic" was coined.  In 1972, Burnstock proposed the 
purinergic neurotransmission hypothesis.  Key points from the hypothesis were: 1) 
purinergic inhibitory neurons are present in the stomach of fish, amphibians, reptiles, and 
birds and that the neurons in the stomach and distal rectum are controlled by 
preganglionic cholinergic fibers in the vagus and pelvic nerves, respectively.  In 
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mammals, however, purinergic inhibitory neurons extend throughout the alimentary tract 
and are controlled by intramural cholinergic neurons; 2) ATP mimicks a prominent 
feature in the autonomic nervous control system, the excitatory action of postganglionic, 
non-cholinergic excitatory nerves in the gut of lower vertebrates, fish, amphibians, and 
mammals. 
 More recent studies show that ATP is a co-transmitter in the peripheral and 
central nervous systems and further illustrate the roles of nucleotides as extracellular 
signaling molecules to non-neuronal cells including endothelial, exocrine and endocrine, 
immune, inflammatory, and secretory cells.  In fact, clear signaling roles for ATP, ADP, 
UTP, and UDP have been established in several tissues to regulate various functions such 
as i) ionotropic, chronotropic, and arrhythmogenic effects in the myocardium, ii) 
gastrointestinal and liver function, iii) regulation of epithelial cellular responses, iv) 
blood flow distribution and oxygen delivery, v) immune responses and control of 
leukocyte trafficking between blood and tissues, and vi) activation and aggregation of 
platelets at sites of vascular injury.  Nucleotides also appear to have potent roles in 
cellular proliferation and growth, induction of apoptosis and anticancer activity, 
atherosclerotic plaque formation, wound healing, and bone formation and resorption. 
 
 
1.8.2. Mechanisms of nucleotide release 
 The release of endogenous nucleotides represents a critical component for 
initiating signal transduction.  Upon cell lysis, massive leaking of nucleotides could 
occur, but this nonspecific mechanism is restricted to organ injury, traumatic shock, or 
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certain inflammatory conditions.  A non-lytic efflux of nucleotides also represents an 
important nucleotide release mechanism. Since ATP is a neurotransmitter, ATP is 
released from excitatory cells into the extracellular space where ATP (and its break down 
products) can activate cell surface purinergic receptors.  One study  shows that in 
addition to adenine nucleotides, other nucleotides are released153.  In addition, cells other 
than excitatory cells can release nucleotides. For example, most resting cells release ATP 
in a basal, constitutive manner, which results in low steady-state concentrations in the 
extracellular milieu due to the competing actions of ATP release and subsequent 
hydrolysis.  Very little is understood regarding the mechanisms of nucleotide release; 
however, the diversity of conditions in which the cells release ATP and/or ADP implies 
multiple nucleotide-releasing pathways.   
 
1.8.2a.  Exocytotic release 
 Various excitatory/secretory tissues such as nerve terminals, platelets, chromaffin, 
mast, and pancreatic acinar cells store ATP and ADP with other neurotransmitters and 
extracellular mediators in specialized granules.  The release of nucleotide-containing 
vesicles in a Ca2+-dependent manner is regulated via exocytosis.  In neurons specifically, 
the regulated exocytosis of ATP is a widely-studied process.   
 
1.8.2b.  Mechanical stimulation 
 Nucleotide release also occurs from non-excitotory tissues, including epithelial 
and endothelial cells, astrocytes, fibroblasts, hepatocytes, bone cells, cardiomyocytes, 
neutrophils, macrophages, and other hematopoietic cells.  These cells have been shown to 
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release ATP transiently under certain mechanical and other stimuli, such as shear stress, 
hypotonic cell swelling, and hypoxia.  Moreover, cells release low nanomolar 
concentrations of ATP at basal rates.  The molecular mechanism of mechanical 
stimulation to release nucleotides from nonexcitatory cells is not fully understood.  
However, the process may involve ATP-binding cassette transporters, plasmalemmal 
voltage-dependent ion channels, and/or connexin hemichannels. 
 
1.8.2c.  Agonist-dependent nucleotide release 
 An increase in extracellular ATP concentrations in endothelial cells has been 
observed upon addition of various GPCR agonists, including thrombin, serotonin, 
acetylcholine, bradykinin, and other Ca2+-mobilizing pharmacological agonists154.  The 
molecular mechanisms of agonist-dependent nucleotide release in the response to 
agonists are poorly understood.   
  
1.8.3.  Extracellular nucleotide metabolism 
 The release of endogenous nucleotides represents a critical component for 
initiating a signaling cascade; thus, extracellular nucleotides need to be rapidly 
inactivated subsequent to signal transduction.  General schemes of extracellular 
nucleotide metabolism include a role for 1) ecto-nucleoside triphosphate 
diphosphohydrolases, 2) ecto-nucleoside pyrophosphatases, 3) alkaline phosphatases, and 
4) ecto-5’-nucleotidases. 
 
1.8.3a.  Ecto-nucleoside triphosphate diphosphohydrolase family 
 45
 Ecto-nucleoside triphosphate diphosphohydrolases (E-NTDPase) hydrolyze 
nucleoside tri- and/or diphosphates, but not monophosphates, and require millimolar Ca2+ 
and Mg2+ concentrations for maximal activity.  Initially, it was assumed that the 
sequential hydrolysis of ATP to ADP and AMP occurred in two steps requiring ATPase 
and ADPase activity.  However, more recent studies suggest that a single ATP-
diphosphohydrolase can hydrolyze both ATP and ADP.  Current nomenclature now 
refers to these enzymes as NTPDases, based on the broad substrate specificity of ecto-
ATPases/ADPases towards different purine and pyrimidine nucleoside tri- and 
diphosphates.   
 There are eight members of the NTPDase protein family.  NTPDase 1, 2, 3, and 8 
are expressed on the cell surface.  These enzymes are highly glycosylated with molecular 
masses ranging from ~70-80 kDa.  NTPDases 1, 2, 3, and 8 show close immunological 
cross-reactivity and may exist in either monomeric or dimeric to tetrameric states.  These 
proteins contain predicted transmembrane domains at the amino and carboxy termini and 
a large extracellular loop containing a central hydrophobic region with five highly 
conserved sequence domains known as the apyrase conserved regions (ACR).  ACR1 and 
ACR4 share a common sequence homology with members of the actin/HSP90/sugar 
kinase superfamily.   
 NTPDases 5 and 6 are intracellular and undergo secretion after heterologous 
expression, while NTPDases 4 and 7 are entirely intracellular, facing the lumen of 
cytoplasmic organelles.  NTPDase proteins can hydrolyze a variety of nucleoside di-and 
triphosphates, although preferences vary among enzymes.  Specifically, the ATP:ADP 
hydrolysis ratios for NTPDases 1, 2, 3, and 8 are ~1-1.5:1, 10-40:1, 3-4:1, and 2:1, 
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respectively.  In addition to their catalytic properties, NTPDase may also function in 
intracellular interactions with the membrane scaffolding protein RanBMP to modulate 
ERK/Ras signaling pathways. 
 
1.8.3b.  Ecto-nucleoside pyrophosphatase family 
 The ecto-nucleoside pyrophosphatase (E-NPP) family consists of seven 
structurally related family members.  This enzyme family exhibits broad substrate 
specificity capable of hydrolyzing pyrophosphate and phosphodiester bonds in nucleotide 
triphosphates, dinucleotides, nucleic acids, nucleotide sugars, choline phosphate esters, 
and lysophospholipids.  NPP1, 2, and 3 are glycosylated proteins with a molecular mass 
of 110 to 125 kDa that share a highly homologous extracellular domain with two 
vibronectin domains and a highly conserved catalytic site.  All three of these NPPs were 
initially thought to be transmembrane proteins with an intracellular amino-terminus, but 
more recent studies have shown that NPP2 is not a transmembrane protein, but is 
synthesized as a pre-pro-enzyme.  Following the removal of the signal peptide and further 
cleavage by a furine-type protease, NPP2 is secreted.  
 NNP1, 2, and 3 are the only family members able to hydrolyze various 
nucleotides while NPP6 and 7 are only able to hydrolyze phosphodiester bonds in 
lysophospholipids or other choline phosphodiesters.  The substrates for NPP4 and 5 are 
currently unknown. 
 
1.8.3c.  Alkaline phosphatase family 
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 Alkaline phosphatases (AP) are ubiquitously expressed and evolutionarily 
conserved from bacteria to humans.  Most APs are homodimeric and each catalytic site 
contains one Mg2+ and two Zn2+ ions, which are necessary for enzymatic activity.  
Mammalian APs display broad substrate specificity towards different phosphomonoesters 
and other phosphorylated compounds, including adenine nucleotides, pyrophosphate, 
inorganic polyphosphates, and bis(p-nitophenyl) phosphate.  Each catalytic reaction 
releases inorganic phosphate and has an optimum pH range from eight to eleven.  Three 
isozymes, intestinal AP, placental AP, and germ cell AP are tissue-specific and are 90-
98% identical.  A fourth isozyme, TNAP, is 50% homologus to the other three isozymes 
and has high expression levels in the bone, liver, and kidney. 
 
1.8.3d.  Ecto-5’-nucleotidase family 
 The ecto-5’-nucleotidase family is expressed in a variety of tissues, including 
colon, kidney, brain, liver, heart, and lung and consists of seven members: five of the 
enzymes are localized in the cytosol, one in the mitochondrial matrix, and one is attached 
to the outer plasma membrane.  The intracellular nucleotidases dephosphorylate 5’-
ribonucleoside monophosphates with low affinity, hydrolyze 5’-dNMPs, and participate 
in salvage pathways and/or de novo nucleotide synthesis. 
 Surface-associated ecto-5’-nucleotidase is also known as CD73 and contains two 
glycoprotein subunits tethered by non-covalent bonds and has a molecular mass of ~60-
70 kDa.  CD73 binds zinc and other divalent metal ions at the amino-terminus and is 
anchored to the plasma membrane at its carboxy terminus by glycosyl-
phosphatidylinositol (GPI).  This enzyme belongs to a large superfamily of dinuclear 
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metallophosphoesterases acting on various substrates such as Ser/Thr phosphoproteins, 
nucleotides, and sphingomyelin. 
 
1.8.4. Purinergic receptors 
 The cellular effects of purines and pyrimidine nucleotides are mediated via a 
family of nucleotide-selective receptors.  Based on pharmacological, functional, and 
cloning data, two major receptor subfamilies, P1 and P2, were described. The P1 
subfamily of receptors is sensitive to adenosine while the P2 subfamily of receptors is 
activated by ADP, ATP, UDP, and UTP.   
 P2 receptors were originally classified based on the rank-order potency of 
nucleotides and nucleotide analogs.  Most of these receptors have been cloned and their 
functions characterized in various heterologous expression systems.  However, their 
functional characterization in native tissues and animals has been limited by the lack of 
agonist and antagonist receptor ligands.  All of the known P2 agonist ligands are 
analogues of ATP, UTP, and ADP and show varying degrees of intrinsic activity and 
susceptibility to extracellular degradation. 
 
1.8.4.a.  Adenosine (P1) receptors 
 Four adenosine-selective P1 receptors, A1, A2A, A2B, and A3 have been cloned.  
Interestingly, all four receptors show species-specific pharmacology.  A1 and A3 
receptors couple to Gi and Go, with the A2 receptors couple to Gs.  Adenosine receptors 
are heterogeneously expressed in a variety of mammalian tissues; including heart, smooth 
muscle, kidney, testis, platelets, leukocytes, and adipocytes.   
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The A1 receptor is expressed in the central nervous system (CNS) and is 
functionally coupled to inhibition of cyclic AMP (cAMP) formation, stimulation of 
potassium conductance, inhibition of N-channel-mediated calcium conductance, 
stimulation of phospholipase C production, and modulation of nitric oxide production.   
 The A2 receptor is categorized into two subtypes, grouped together based on their 
capacity to activate adenylate cyclase.  The A2A receptor has a high affinity for adenosine, 
signals through N- and P- type Ca2+ channels, and is localized in the striatum, nucleus 
accumbens, and olfactory tubercle regions of the mammalian brain.  The A2B receptor has 
a lower affinity for adenosine and is more ubiquitously expressed in the CNS.  The 
functional significance of A2B expression in the brain, however, is unknown due to a lack 
of receptor-specific ligands. 
 The A3 receptor was the first P1 receptor identified by cloning, rather than by 
pharmacologic properties.  Activation of the A3 receptor leads to inhibition of adenylyl 
cyclase and elevation of inositol-1,4,5-triphosphate (IP3) levels and intracellular Ca2+.  A3 
receptors are involved in the regulation of mast cell function, eosinophil apoptosis, and 
preconditioning that occurs during ischemic reperfusion of the heart that protects against 
myocardial infarction.  
 
1.8.4b.  P2X receptors 
 The P2X receptors are ATP-gated ion channels that form a nonselective pore 
permeable to Ca2+, K+, and Na+ and mediate rapid neurotransmission events.  There are 
seven receptor subtypes: P2X1-P2X7.  Each receptor shares a common structure of 
intracellular N- and C-termini, two transmembrane-spanning regions (2TM), one at each 
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terminus, and a large extracellular domain.  A functional P2-receptor channel consists of 
three subunits, which can be homomeric or heteromeric combinations of the various P2X 
subunits. To date, P2X1/5, P2X2/3, and P2X4/6 have been identified as functional 
heteromers.  Whereas most P2X subunits can form functional homomers, P2X5 and P2X6 
receptors do not, and instead appear to function only as heteromers with other P2X 
receptor subtypes.  Currently, little information is available on the agonist (ATP) binding 
site on P2X receptor constructs or on ancillary sites that may modulate receptor function. 
 
1.8.4c.  P2Y receptors 
 P2Y receptors are G protein-coupled receptors that are activated by purine or 
pyrimidine nucleotides.  P2Y receptors were first cloned and characterized in the early 
1990s.  Once the first P2Y receptor, termed P2Y1, was cloned, additional members were 
subsequently identified through sequence homology searches, expression cloning 
techniques, or library screening with probes of previously identified P2Y receptors. There 
are eight verified family members, P2Y1, P2Y2, P2Y4, P2Y6, P2Y11, P2Y12, P2Y13, and 
P2Y14. These receptors are further subdivided into the P2Y1 and the P2Y12 receptor 
subfamilies, based on their sequence homology and G-protein coupling properties (see 
below and Table 1.3).  On numerous occasions, orphan receptors were wrongly identified 
as P2Y receptors, resulting in gaps in the P2Y receptor nomenclature. 
 The P2Y receptor family differs from other GPCR families in that their members 
have low sequence identity despite similar pharmacological profiles.  For example, the 
human P2Y1 and P2Y11 receptors, both of which are coupled to Gq and are activated 
primarily by adenine nucleotides, share only 33% homology.  The regions with the 
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highest degree of identity between P2Y receptors lay within the TM 3, 6, and 7 domains 
of the receptors close to the intracellular loops.  Interestingly, these TM domains are 
likely to contribute to the binding of agonists and may subsequently be involved in the 
signal transduction of the heterotrimeric G protein.  The conserved sequence of TM 3, 
SILFLTCIS, is found in all cloned and functionally defined P2Y receptors with the 
exception of the P2Y4 (SVLFLTCIS) and P2Y11 (SVIFLTCIS) receptors. 
 
1.8.4i.  P2Y1 receptor subfamily 
 The P2Y1 receptor subfamily consists of P2Y1, P2Y2, P2Y4, P2Y6, and P2Y11 
receptors.  These receptors couple to Gαq to activate phospholipase C beta (Table 1.3).  It 
should be noted that the P2Y11 receptor is dually coupled to both Gq and Gs, resulting in 
dual stimulation of phospholipase C and adenylyl cyclase. 
 
P2Y1 receptor 
 The prototypical P2Y1 receptor was the first family member identified, and was 
originally cloned from chicken brain.  Subsequent homologues were cloned and 
characterized from turkey, cow, rodent, human, and skate.  P2Y1 receptors are widely 
distributed in various tissues, including brain, lung, platelets, and endothelia, and are 
activated potently by adenine dinucleotides and by adenine trinucleotides to a lesser 
extent.  One primary function of the P2Y1 receptor is regulation of platelet aggregation, 
in which it plays an essential role in ADP-induced shape change.  Platelet aggregation in 
P2Y1 -/- mice is inhibited155.  In addition, prolonged bleeding time and protection from 
collagen- and ADP-induced thromboembolism is observed.  The P2Y1 receptor is also 
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involved in ion channel regulation, renal function, and vasodilation via stimulation of 
nitric oxide. 
 
P2Y2 receptor 
 The second cloned P2Y receptor, P2Y2, was the first family member identified 
that was activated by uracil nucleotides.  The receptor was cloned by expression cloning 
in Xenopus oocytes and monitoring for nucleotide-promoted Ca2+-activated Cl- currents.  
The receptor is expressed in various tissues including lung, kidney, and hematopoietic 
cells.  In addition to being activated by UTP, the P2Y2 receptor is equipotently activated 
by ATP.  This unique activation by UTP and ATP has been used identify this receptor.  A 
role for P2Y2 receptors in regulation of Cl- secretion in airway epithelia has been 
established156.  Subsequently, a similar physiological role for P2Y2 receptors in nasal 
epithelia and in cells found in the lacrimal gland and gastrointestinal tract was identified.   
Cystic fibrosis (CF) is a genetic disease that results in an absent or malfunctioning 
cystic fibrosis transmembrane regulator (CFTR) protein.  A defective or missing CFTR 
results in abnormal Cl- conductance on the apical membrane of the epithelial cell and 
ultimately, airway surface liquid depletion.  Because airway surface liquid is essential to 
support ciliary stability and function, ciliary collapse and decreased mucociliary transport 
occur as a result, leading to phlegm retention, infection, and inflammation. 
Since P2Y2 regulates Cl- secretion by activating a Ca2+-activated Cl- current 
independent of the mechanism used by the CFTR, P2Y2 may be used as a therapeutic CF 
target.  A P2Y2 agonist is currently in clinical trials for the treatment of CF to test the 
hypothesis that activating P2Y2 would lead to downstream Cl- channel activation and 
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subsequent restoration of the aqueous layer in the lumen of airway cells156.  Restoration is 
normally facilitated by the cystic fibrosis transmembrane regulator (CFTR), but is 
defective in CF patients. 
 
P2Y4 receptor 
 The P2Y4 receptor was the second uracil nucleotide-activated P2Y receptor 
identified.  This receptor is distributed in smooth muscle, lung, and jejunum tissue.  
Interestingly, the P2Y4 pharmacological profile is species-dependent.  For example, the 
human orthologue is activated by UTP but not ATP, with ATP acting as an antagonist.  In 
rodent orthologues, however, UTP and ATP are equally potent agonists.  Recently it has 
been shown that the P2Y4 receptor is involved in differentiation and cell death of human 
neuroblastoma cells157. 
 
P2Y6 receptor 
 The P2Y6 receptor was originally cloned from rodent tissue, followed by 
identification of the human homologue, and is the third receptor to be activated by uracil 
nucleotides.  UDP is a potent activator of this receptor, and it is weakly activated if at all 
by ADP, ATP, and UTP.  This receptor is expressed in a variety of tissue, including the 
aorta, kidney, brain, and lung.  P2Y6 receptors are also expressed in T-cells and are 
implicated in regulating the infiltration of these cells into the colon, leading to damage of 
the epithelial lining and inflammatory bowel disease.  In addition, the P2Y6 receptor was 
recently found to be up-regulated in neurons when are damaged, and could function as a 
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sensor for phagocytosis by sensing diffusible UDP signals153,158.  This is a previously 
unknown pathophysiological function of P2Y receptors in microglia. 
 
P2Y11 receptor 
 Unlike the other P2Y family members, P2Y11 can couple to both Gαq and Gαs to 
activate both PLC and adenylyl cyclase signaling pathways.  However, the receptor is 
coupled to activation of PLC at much lower agonist concentrations compared to adenylyl 
cylcase activation.  Interestingly, a rodent orthologue does not exist.  However, a canine 
P2Y11 receptor was cloned and it also couples to both PLC and adenylyl cyclase 
activation.  While there is 70% homology between species, different pharmacologic 
properties between the human and canine receptors exist.  The human P2Y11 receptor is 
more potently activated by ATP than ADP and is insensitive to 2-thioether substitutions 
in the adenine ring.  In contrast, the canine P2Y11 receptor is activated more potently by 
ADP than ATP and is sensitive to the 2-thioether substitution.  The differences in ADP 
versus ATP potencies was shown to be due primarily to a single amino acid substitution 
of Arg-265, located at the juxtaposition of TM6 and the third extracellular loop, in the 
human receptor to Gln in the canine receptor, while the amino acid(s) responsible for the 
sensitivity to 2-thioether substitution was not identified. The P2Y11 receptor regulates 
several physiologic responses, including cardiac function, platelet aggregation and 
smooth-muscle cell proliferation. 
 
1.8.4ii.  P2Y12 receptor subfamily 
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 The P2Y12 receptor subfamily consists of the P2Y12, P2Y13, and P2Y14 receptors.  
These receptors all couple to Gαi to inhibit adenylyl cyclase and activate potassium 
channels (Table 1.3).   
 
P2Y12 receptor 
 In the early 1960s, studies showed that adding ADP to platelets induced 
aggregation via an unidentified receptor referred to as the P2T receptor.  Later studies 
showed that in platelets, ADP promoted the inhibition of adenylyl cyclase and an increase 
of intracellular calcium, suggesting either that there was one receptor coupled to two 
signaling pathways, or that there were two receptors activated by ADP coupled to two 
different signaling pathways. While the P2Y1 receptor was eventually identified as the 
receptor coupled to PLC stimulation and increased intracellular Ca2+ mobilization, the 
receptor leading to inhibition of ADP-promoted adenylyl cyclase remained unknown. 
 The P2Y12 receptor (also referred to as P2YADP, P2YAC, P2YCYC, and P2TAC) was 
ultimately identified as the Gαi-coupled receptor involved in platelet aggregation in 2001.  
In contrast to the ubiquitous expression of other P2Y receptors, P2Y12 receptor 
expression is limited to platelets and the brain.  In addition to activation by ADP, 
2MeSADP is also an agonist while adenosine monophosphates such as 2MeSAMP are 
antagonists. 
  
P2Y13 receptor 
 The function of the ADP-activated P2Y13 receptor is poorly understood due to the 
lack of studies available for the Gαi-coupled receptor.  P2Y13 receptors are distributed in 
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the brain, lymph nodes, bone marrow, spleen, and liver.  This distribution suggests that 
the P2Y13 receptor may have a role in regulating immune responses and/or 
haematopoiesis.  For example, one study suggests that the P2Y13 receptor may be a 
potential therapeutic target in the treatment of atherosclerosis through its regulatory role 
in the regulation of cholesterol homeostasis.  A recent study shows that RhoA/ROCK I 
signaling downstream of the P2Y13 receptor controls HDL endocytosis in human 
hepatocytes. 
 
P2Y14 
 The P2Y14 receptor is unique from the other P2Y receptors because it is activated 
by UDP sugars (UDP-glucose, UDP-galactose, and UDP-N-acetylglucosamine).  This 
receptor is found in various tissues, including moderate expression in lung, spleen, brain, 
and heart, and high expression in neutrophils, placenta, adipose tissue, intestine, and 
stomach and skeletal muscle.  The physiological function of the P2Y14 receptor is not 
clearly understood, although increasing evidence supports a role in immune function.  
 
1.9.  Role of purinergic receptors in platelet activation 
 Purinergic receptors regulate a variety of physiological processes in multiple cell 
types, including ion transport and stress response in epithelial cells, vascular smooth 
muscle relaxation, and platelet activation.  Vascular injury leads to the exposure of sub-
endothelial collagen, activation of platelets, and the initiation of the coagulation cascade.  
Platelet activation is characterized by rapid shape change, release of granular contents, 
generation of lipid mediators, and aggregation.  Secondary mediators, such as ADP 
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released from granules and thromboxane A2, activate other resting platelets, resulting in 
amplification of initial physiological haemostatic response. 
 Platelet activation is achieved through various surface receptors that include 
GPCRs, integrins, and glycoprotein receptors.  Adenosine nucleotides that are secreted 
following platelet activation signal through purinergic receptors on the platelet membrane 
(Figure 1.3).  The P2 receptors expressed on the cell surface of platelets are the P2Y1, 
P2Y12, and P2X1 subtypes, whose agonists are ADP, ADP, and ATP, respectively.  
Agonist activation of these receptors initiates a complex signaling cascade that ultimately 
results in platelet activation and thrombus formation. 
 
1.9.1.  P2Y1 receptor 
 The P2Y1 receptor is required for ADP-induced platelet shape change and 
aggregation.  Platelets from P2Y1 receptor (-/-) mice display severely impaired platelet 
aggregation upon exposure to collagen and agonists for the TPα and protease-activated 
receptors.  These platelets also show a loss in ADP-mediated intracellular calcium 
mobilization, a key step in platelet signaling.  In addition, transgenic mice that over-
express P2Y1 receptors exhibit a decrease in bleeding time in vitro and in vivo. 
 The P2Y1 receptor also is important for Gαq signaling.  Activation of the Gαq-
coupled serotonin receptor in the presence of P2Y1 receptor antagonists results in platelet 
aggregation155.  Additionally, although serotonin cannot cause platelet activation alone, it 
can restore the ADP response in P2Y1 receptor-deficient platelets by promoting Ca2+ 
mobilization and thereby functionally substituting for the P2Y1 receptor. 
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1.9.2. P2Y12 receptor 
 The role of the Gαi-coupled P2Y12 receptor in platelet function was investigated 
using pharmacological and mouse models.  P2Y12 receptor antagonists include AR-C 
compounds, 2MeSAMP, and metabolites of thienopyridines, clopidogrel, ticlopidine, and 
CS-747.  AR-C compounds showed that the P2Y12 receptor does not contribute to platelet 
shape change, but enhances other agonist-induced dense granule release.  The ADP-
induced Gαi signaling is necessary but not sufficient for fibrinogen receptor activation 
and platelet aggregation, and thromboxane generation. 
 Platelets from P2Y12 -/- mice display severely inhibited ADP-induced rates of 
aggregation, are insensitive to clopidogrel treatment, and show prolonged bleeding times, 
with no effects on P2Y1 receptor-mediated shape change or intracellular Ca2+ 
mobilization159.  Thrombin-induced platelet aggregation is also compromised.  Most 
importantly, patients with dysfunctional P2Y12 receptor expression suffer from a severe 
defect in ADP-induced adenylyl cyclase inhibition and platelet aggregation, but retain 
normal platelet shape change. 
 The P2Y12 receptor is the therapeutic target of ticlopidine and clopidogrel, two 
platelet aggregation inhibitors used for prevention and treatment of arterial thrombosis.  
Several experimental models show that clopidogrel (PLAVIX) is a potent anti-aggregant 
and antithrombotic drug.  Clopidogrel was released into the market following a 
successful clinical trial showing superior efficacy versus aspirin in preventing myocardial 
infarction, stroke, and vascular death.   
Clopidogrel is a pro-drug that is oxidized by hepatic P450 enzymes to the activate 
metabolite, which irreversibly inhibits ADP-promoted platelet aggregation by binding to 
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the P2Y12 receptor and covalently reacting with a cysteine residue in the receptor that is 
required for activity160-161.  ADP-promoted platelet shape change is not affected by 
clopidogrel, indicating that this response is regulated by the P2Y1 receptor160,162-163.   
 
1.9.3.  P2X1 receptor 
 Ubiquitously expressed P2X1 receptors are the third category of purinergic 
receptors implicated in the regulation of platelet function.  These receptors are non-
selective cation channels primarily activated by physiological agonists such as 
extracellular ATP.  Activation of P2X1 receptors leads to a transient shape change, but 
fails to induce the formation of long filopodial extensions.  This is due to transient influx 
of calcium resulting from receptor activation.  In addition to shape change, activated 
P2X1 receptors cause centralization of granules, but do not lead to the release of granular 
contents.  The relevance of the granular movements remains unclear.  Finally, animals 
deficient in P2X1 display normal bleeding times, but display increased resistance to 
thrombosis.  Conversely, animals overexpressing the P2X1 receptor show increased 
thrombin formation in response to injections of collagen and epinephrine. 
 
1.9.4.  Regulation of purinergic receptors in platelets 
Regulation of the ADP response in platelets is critical in understanding platelet 
activation. It is established that ADP released from isolated platelets causes them to 
become refractory to activation by ADP in vitro159. A recent study demonstrated that in 
platelets, the P2Y1 receptor was rapidly desensitized upon addition of ADP, while the 
P2Y12 was refractory to desensitization164.  It has also been reported that the P2Y1 
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receptor was rapidly internalized in both platelets and 1321N1 cells in an agonist-
dependent manner165.  Finally, in a study quantifying the kinetics of desensitization, the 
data show that the P2Y1-selective agonist MRS2365 causes very rapid desensitization of 
subsequent ADP-promoted platelet aggregation, with a half-life of desensitization of 18 
sec166. Thus, it is clear that the desensitization and internalization of the P2Y1 receptor is 
an important means for regulating platelet function. 
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Table 1.1.  Examples of top-selling drugs targeting G protein-coupled receptors 
(GPCRs).   
 
Trade Name 
(Generic Name) 
Therapeutic 
Use 
Mechanism of 
Action 
Name of 
Company 
World Sales 
(USD millions)
Allegra 
(fexofenadine) 
Allergies H1 antagonist Sanofi-Aventis 1792 
Imigran 
(sumatriptan) 
Migraines 5HT1D agonist GlaxoSmithKline 1454 
Plavix 
(clopidogrel) 
Stroke P2Y12 antagonist Bristol-Myers 
Squibb 
5277 
Serevent 
(salmeterol) 
Asthma Β1 agonist GlaxoSmithKline 679 
 
GPCR drugs cover many therapeutic uses and represent a substantial population of 
today’s market.  Source:  IMS Knowledge Link; reported world sales are 12 months to 
the end of the first quarter of the 2005 fiscal year. 
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Table 1.2.  Summary of protease-activated receptor (PAR) activating proteases, 
activating peptides, tissue distribution, and PAR-deficient mice phenotype. 
 
Receptor Activating 
proteases 
Synthetic/activating 
peptide (AP) 
Tissue 
distribution 
Knockout mouse 
phenotype 
PAR1 Thrombin, 
FXa, FVIIa, 
APC, MMP, 
plasminogen 
SFLLRN, TFLLRN Human 
platelets, 
fibroblasts, 
neurons, 
astrocytes, 
endothelium, 
epithelium 
Partial embryonic 
lethality 
PAR2 Trypsin, 
tryptase, 
FVIIa, FXa 
SLIGKV Fibroblasts, 
myocytes, 
neurons, 
astrocytes, 
epithelium, 
endothelium 
Impaired leukocyte 
migration; impaired 
allergic 
inflammation of 
airway, joints, 
kidney 
PAR3 Thrombin None Mouse 
platelets, 
endothelium, 
myocytes, 
astrocytes  
Protection against 
thrombus 
formation/pulmonary 
embolism 
PAR4 Thrombin AYPGKF, 
GYPGQV 
Human 
platelets, 
endothelium, 
myoctes, 
astrocytes 
Protection against 
thrombus 
formation/pulmonary 
embolism 
APC, activated protein C; MMP, matrix metalloprotease 
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Table 1.3.  Summary of P2Y receptor signaling and tissue expression 
 
Receptor Nucleotide 
selectivity 
G protein-
coupling 
Effectors Tissue 
distribution 
P2Y1 2 MeSADP >   
2 MeSATP ~ 
ADP 
 
Gq PLC Brain, lung, 
platelets, 
endothelia 
P2Y2 UTP ~ ATP 
 
Gq PLC Lung, kidney, 
hemato-poietic 
cells 
P2Y4 UTP Gq PLC Smooth muscle, 
lung, jejunum 
 
P2Y6 UDP >> UTP Gq PLC Aorta, kidney, 
brain, lung 
P2Y11 ATP >> ADP Gq and Gs PLC, AC Spleen, mono-
cytes, kidney 
P2Y12 2MeSADP > 
ADP 
Gi AC, K+ 
channels? 
Platelets, brain 
 
P2Y13 2MeSADP ~ 
ADP 
Gi AC, K+ 
channels? 
Brain 
P2Y14 UDP-glucose > 
UDP-galactose 
Gi AC, K+ 
channels? 
Lung, 
neutrophils 
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Figure 1.1.  Classical G protein-coupled receptor internalization and trafficking 
paradigm.  The general dogma of GPCR internalization and trafficking is based off 
β2AR studies.  Upon agonist stimulation, the receptor is rapidly phosphorylated (P) to 
recruit arrestin3 (Arr3).  In addition, the receptor and arrestin protein are ubiquitinated 
(Ub) via Mdm2, internalized via clathrin coated pits, and sorted to recycling endosomes.  
Upon short agonist stimulation, the receptor is recycled back to the plasma membrane 
and is ready for re-activation.  However, upon prolonged exposure to agonist, the β2AR is 
sorted to lysosomes and degraded.                                                                                                       
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 Figure 1.2.  The clathrin adaptor protein interaction web.  A schematic 
representation of the protein-protein interactions between clathrin, AP-2, and endocytic 
adaptor proteins.  The sorting signal or putative cargo types recognized by the different 
adaptors are boxed in black.  pGPCR, phosphorylated G protein-coupled receptor; PIP2, 
PtdIns(4,5)P2. 
 
 66
Gq
Gi
Gq Gi G12/13 Gq G12/13
Gq G12/13
Gq
G12/13
P2Y1
P2Y12
AD
P
PAR1 PAR4
TP-α
TP-β
TXA
2
α-Thr
PLC-β
Ca2+
flux
GPIIb–IIIa
activation
GPIa–IIa GPVI -FCRγ
vWF
collagen
α2β1
 
 
 
Figure 1.3.  Schematic of the major adhesion and agonist receptors on the surface of 
platelets.  Platelets have a variety of cell-surface receptors that mediate their activation, 
adhesion to the blood vessel wall, and their aggregation with each other. Three G protein-
coupled receptor families exist on the platelet surface and are linked to one or more 
different G proteins.  ADP receptors:  P2Y1 and P2Y12 which are linked to Gq and Gi, 
respectively.  Thrombin receptors: PAR1 and PAR4, which are linked to Gi,q,12/13 and 
Gq,12/13, respectively. TXA2 receptors: TP-  and TP- , each of which is linked to Gq and 
G12/13. All of these receptors activate specific signalling cascades that are ultimately 
linked to the mobilization of calcium from intracellular stores.  GPIIb–IIIa functions in a 
range of platelet responses, including platelet aggregation, spreading and clot retraction. 
GPIa–IIa and α2β1 integrins support platelet adhesion on collagen. The GPVI receptor 
FcR -chain complex supports platelet adhesion and activation on fibrillar collagens. 
PAR, protease-activated receptors; PLC, phospholipase C; TXA2, thromboxane A2; TP, 
thromboxane/prostanoid receptors; vWf, von Willebrand factor. 
 67
XII XIIa 
Intrinsic 
Pathway 
Tissue Factor XI XIa 
IXa 
VIIIa 
IX 
Extrinsic 
Pathway 
VIIa VII 
X Xa 
Va 
Thrombin (IIa) Prothrombin (II) 
Clotting          
Platelet Aggregation Fibrin Fibrinogen  
 
Figure 1.4.  Coagulation cascade.  The coagulation cascade has two pathways, intrinsic 
and extrinsic pathways that lead to fibrin formation, clotting, and platelet aggregation.  
The pathways are a series of reactions, in which a serine protease zymogen is activated to 
become an active component that then catalyzes the next reaction in the cascade.   
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Chapter 2 
 
Protease-activated Receptor 2 is Essential for Factor VIIa and Xa-Induced Signaling, 
Migration, and Invasion of Breast Cancer Cells 
 
2.1. Abstract 
 Protease-activated receptors (PARs) are G protein-coupled receptors (GPCRs) that 
function as cell surface sensors for coagulant proteases, as well as other proteases associated 
with the tumor microenvironment. PAR1 is activated by thrombin, whereas the upstream 
coagulant protease VIIa bound to tissue factor and Xa can activate both PAR1 and PAR2. 
PAR1 has been implicated in tumor cell growth, migration and invasion, whereas the 
function of PAR2 in these processes is largely unknown. Towards defining the functional 
importance of PAR2 in cancer cells, we used small interfering RNAs (siRNAs) to deplete 
highly invasive breast cancer cells of endogenous PAR proteins. Our findings strongly 
suggest that PAR2 is critical for MDA-MB-231 and BT549 breast cancer cell migration and 
invasion towards NIH-3T3 fibroblast conditioned medium. To define the relative importance 
of PAR1 versus PAR2 in mediating factors VIIa and Xa responses, we assessed signaling in 
cancer cells lacking either endogenous PAR1 or PAR2 proteins. Strikingly, in MDA-MB-231 
cells depleted of PAR2, we observed a marked inhibition of VIIa and Xa signaling to 
phosphoinositide hydrolysis and ERK1/2 activation, whereas signaling by VIIa and Xa 
remained intact in PAR1 deficient cells. Factors VIIa and Xa-induced cellular migration was 
also impaired in MDA-MB-231 cells deficient in PAR2 but not in cells lacking PAR1. 
Together these studies reveal the novel findings that PAR2, a second protease-activated 
GPCR, has a critical role in breast cancer cell migration and invasion and functions as the 
endogenous receptor for coagulant proteases VIIa and Xa in these cells.  
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2.2. Introduction 
 A link between malignant cancer and hyperactivation of the coagulation system is 
well documented in the literature 1-4. However, the mechanism by which coagulant activity 
contributes to tumor cell invasion and metastasis remains poorly understood. The expression 
of tissue factor, the principal cellular activator of the coagulation cascade, on cancer cells 
leads to generation of active coagulant proteases on the cell surface 5. Thrombin, the main 
effector protease of the coagulation cascade, is thought to promote metastasis, at least in part, 
by facilitating tumor cell interactions with host vascular cells including platelets and 
endothelial cells lining blood vessels 6-8. Thrombin and upstream coagulant proteases are also 
generated in the tumor microenvironment independent of blood coagulation 2, and potentially 
contribute to cancer cell migration and invasion by acting directly on tumor cells. Thus, 
coagulant proteases are likely to facilitate tumor cell metastasis by modulating a number of 
host vascular cell responses, as well as acting directly on tumor cells themselves. 
Thrombin is formed during a series of zymogen conversions that are triggered when 
coagulant proteases contact tissue factor. Tissue factor, a single spanning integral membrane 
protein, complexed with VIIa cleaves factor X to generate the active protease Xa. The 
formation of Xa is localized to the cell surface and triggers proteolytic conversion of 
prothrombin to thrombin. In addition to cleaving fibrinogen, thrombin activates cells through 
at least three G protein-coupled protease-activated receptors (PARs): PAR1, PAR3 and 
PAR4. In contrast, PAR2 is activated by multiple trypsin-like serine proteases, including the 
upstream coagulant proteases VIIa and Xa, but not by thrombin. Thrombin is the main 
physiological activator of PAR1; however, activation of PAR1 is not restricted to this 
protease. PAR1 can be cleaved and activated by tissue factor-VIIa and Xa 9-10, plasmin 11, 
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activated protein C 12, and metalloproteases 13. Clearly, multiple proteases can cleave and 
activate these receptors, and thus the particular PAR and protease that function in a specific 
cellular setting remains largely undefined. 
 PAR1 has been implicated in tumor cell growth, invasion and metastasis of several 
types of human malignant cancers, including breast. PAR1 expression has been directly 
correlated with the degree of invasiveness exhibited by primary human breast tissue 
specimens and established cancer cell lines, whereas PAR1 expression is minimal or absent 
in benign and normal breast tissue and non-invasive carcinoma 14-17.  Ectopic expression of 
PAR1 in mouse mammary gland epithelia induces an oncogenic phenotype 18, and PAR1 also 
has the capacity to transform NIH-3T3 fibroblasts, further suggesting a role for this receptor 
in oncogenesis 19. Moreover, expression of PAR1 in non-invasive breast carcinoma is 
sufficient to promote growth and invasion of breast cancer cells in a xenograft nude mouse 
model 13. PAR2 is also expressed in malignant breast tissue and in highly invasive breast 
carcinoma cell lines 15,20. However, in contrast to PAR1, the functional importance of PAR2 
in breast cancer cells is largely unknown. While activation of PAR1 with thrombin or matrix 
metalloproteinase-1 occurs on breast carcinoma 13-14,21, the actual protease responsible for 
PAR2 activation remains to be determined. Interestingly, the upstream coagulant proteases 
VIIa and Xa have also been reported to stimulate signaling and migration of certain breast 
carcinoma cells 22-23; however, whether this involves direct activation of PAR1 and/or PAR2 
has not been clearly defined. 
  We hypothesize that besides thrombin, other tumor cell-generated proteases activate 
PAR1, and perhaps PAR2, to promote breast cancer cell invasion and metastasis. Tissue 
factor is highly overexpressed in invasive tumor cells and is responsible for generation of 
 4
active coagulant proteases VIIa and Xa. Factors VIIa and Xa potentially make important 
contributions to cancer cell invasion and metastasis via activation of PAR1 and/or PAR2. In 
the present study, we used small interfering RNAs (siRNAs) to knockdown endogenous 
PAR2 protein in an effort to define the importance of this receptor in breast cancer cells. Our 
findings strongly suggest that PAR2 is an important mediator of breast cancer cell migration 
and invasion. Our studies further demonstrate an essential role for PAR2 in mediating 
coagulant protease VIIa and Xa-induced signaling and migration of MDA-MB-231 breast 
cancer cells. These findings are the first to demonstrate a critical role for PAR2 in mediating 
cancer cell migration and invasion and also define a new role for PAR2 as the endogenous 
receptor for factors VIIa and Xa in invasive breast cancer cells. Moreover, these studies are 
the first to demonstrate the relative contribution of PAR1 versus PAR2 in mediating 
coagulant protease effects on breast cancer cells and provide important information for the 
design and use of protease inhibitors in breast cancer disease.  
 
2.3. Materials and methods 
 
2.3.1. Reagents and antibodies 
 
 Human α-thrombin, plasma-derived factor Xa, and factor VIIa were purchased from 
Enzyme Research Laboratories (South Bend, IN).  Collagen type IV, laminin, and α-trypsin, 
treated with tosylamide-2-phenylethyl chloro-methyl ketone, were purchased from Sigma-
Aldrich (St. Louis, MO).  PAR1-selective agonist peptide (TFLLRNPNDK) and PAR2-
selective agonist peptide (SLIGKV) were synthesized as the carboxyl amide and purified by 
reverse-phase high-pressure liquid chromatography (University of North Carolina Peptide 
Facility, Chapel Hill, NC). 
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 A rabbit polyclonal anti-PAR1 antibody was generated against the hirudin-like 
domain peptide sequence YEPFWEDEEKNESGLTEYC as previously described 24.  The 
monoclonal anti-PAR2 antibody SAM11 was generously provided by Dr. Lawrence Brass 
(University of Pennsylvania, PA).  Anti-actin antibody was purchased from Sigma-Aldrich.  
Monoclonal anti-phospho-p44/42 mitogen-activated kinase (MAPK); extracellular signal-
related kinase (ERK) 1/2 antibody and polyclonal anti-p44/42 MAPK (ERK1/2) antibody 
were purchased from Cell Signaling Technology, Inc. (Beverly, MA).  Horseradish 
peroxidase (HRP)-conjugated goat anti-mouse and anti-rabbit antibodies were from Bio-Rad 
(Hercules, CA). 
 
2.3.2. Cell lines 
 MDA-MB-231 and BT549 cell lines were purchased from American Type Culture 
Collection (Manassas, VA).  MDA-MB-231 cells were cultured in Leibovitz’s L-15 medium 
supplemented with 10% fetal bovine serum (FBS).  BT549 cells were grown in RPMI 1640 
medium supplemented with 10% FBS and 10 µg/mL insulin. 
 
2.3.3. Phosphoinositide hydrolysis 
 MDA-MB-231 cells were seeded at 1.6 x 105 cells per well in 24-well dishes.  Cells 
were labeled with 2 µCi/mL of myo-[3H]inositol in inositol- and serum-free medium 
containing 1 mg/mL bovine serum albumin (BSA) overnight.  Cells were then washed and 
incubated in the absence or presence of agonists diluted in medium containing 1 mg/mL BSA 
and 20 mM lithium chloride for 1 hour at 37ºC.  Cell medium was removed and total cellular 
[3H]inositol phosphates were extracted, isolated, and quantified as described 25. 
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 2.3.4. siRNA electroporation 
 MDA-MB-231 and BT549 cells (1 x 106) were electroporated with 600 nM of PAR1-
specific (5’-AGAUUAGUCUCCAUCAAUA-3’), PAR2-specific (5’-
GGAAGAAGCCUUAUUGGUA-3’), or nonspecific control siRNA (5’-
GGCUACGUCCAGGAGCGCACC-3’) using a system developed by Amaxa, Inc. 
(Gaithersburg, MD).  Cells were then plated in normal growth media.  PAR-specific siRNAs 
were synthesized by Dharmacon, Inc. (Lafayette, CO). 
 
2.3.5. Immunoblotting for PAR expression 
 To assess PAR1 or PAR2 protein expression, MDA-MB-231 cells were seeded at 1 x  
106 cells/well in a six-well plated and grown for 24, 48, and 72 hours after siRNA 
electroporation.  Cells were then lysed in 1% Triton X-100 lysis buffer containing 50 mM 
Tris-HCl (pH 7.4), 100 mM NaCl, 5 mM EDTA, 50 mM NaF, and 10 mM sodium 
pyrophosphate with protease inhibitors.  Equal amounts of protein lysates (~30 µg) were 
resolved by SDS-PAGE, transferred to polyvinylidene difluoride membranes, and probed 
with anti-PAR1 or anti-PAR2 antibodies.  Membranes were then stripped and re-probed with 
a monoclonal anti-actin antibody.  Immunoblots were developed with enhanced 
chemiluminescence plus (Amersham Biosciences, Inc., Piscataway, NJ) and imaged by 
autoradiography. 
 
2.3.6. Cell-surface ELISA 
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 MDA-MB-231 cells electroporated with siRNAs were seeded on fibronectin-coated 
24-well plates at 1.6 x 106 cells/well.  After 72 hours, cells were incubated with anti-PAR1, 
anti-PAR2 antibody, or pre-immune serum for 1 hour at 4ºC.  Cells were then washed to 
remove unbound antibody, fixed with 4% paraformaldehyde, and then incubated with goat-
anti rabbit antibody conjugated to HRP for 1 hour at 25ºC.  Cells were then washed and 
incubated with HRP substrate, One-Step ABTS (2,2’-azino-bis-3-ethylbenzthiazoline-6-
sulfonic acid, Pierce).  The optical density was determined at 405 nm using a Molecular 
Devices (Sunnyvale, CA) SpectraMax Plus microplate reader. 
 
2.3.7. ERK1/2 activation 
 MDA-MB-231 cells were seeded at a density of 1.6 x 105 cells/well.  Cells were then 
serum-starved overnight and incubated in the absence or presence of agonists for 30 minutes 
at 37ºC.  Following incubation, cells were lysed in 2x SDS-gel loading buffer [100 mM Tris-
HCL (pH 6.8), 20% glycerol, 4% SDS, 0.02% bromophenol blue].  Cell lysates were 
resolved by SDS-PAGE, transferred to membranes, and immunoblotted with an anti-
phospho-p44/42 MAPK (ERK1/2) antibody.  To detect total p44/42 MAPK (ERK1/2), 
membranes were stripped and re-probed with an anti-p44/42 MAPK (ERK1/2) antibody.  
Immunoblots were developed and imaged by autoradiography. 
 
2.3.8. Cellular Migration 
 Cell migration was assessed using a 24-well format containing a transwell insert (8-
µm pore size polycarbonate filter) (BD Biosciences) that was coated with 7.5 µg/ml collagen 
type IV for MDA-MB-231 cells or 10 µg/ml laminin for BT549 cells.  After 72 hours of 
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electroporation with siRNAs, serum-deprived MDA-MB-231 and BT549 cells (5 X 104 
cells) were diluted in 100 µl of DMEM containing 0.1% BSA and 10 mM HEPES, pH 7.4 
and added to the upper chamber of the transwell.  Cells were then allowed to migrate in 
response to the addition of 600 µl of either serum-free media, NIH-3T3 fibroblast-
conditioned medium or to various agonists added to the lower chamber for 3 h at 37C. Non-
migrated cells in the upper chamber were removed by wiping with a cotton swab, while the 
attached migrated cells were fixed and stained with 0.1% crystal violet diluted in 0.1 M 
borate, pH 9.0 and 2% ethanol. Three different fields of cells were photographed with IX81 
Olympus microscope fitted with a 20X objective and the number of migrated cells in each 
field was counted. 
 
2.3.9. Cellular invasion 
 After 72 hours of electroporation with siRNAs, serum-starved MDA-MB-231 cells (1 
x 105) or BT549 cells (5 x 104) diluted in 100 µl of DMEM (without phenol red) containing 
0.1% BSA, 10 mM HEPES (pH 7.4) were added to the upper well of a 24-well transwell 
insert coated with matrigel (BD Biosciences).  The lower well contained 600 µl of NIH 3T3 
fibroblast conditioned medium prepared as previously described 26.  Cells were then 
incubated for 24 hours at 37ºC.  Cells remaining in the upper chamber were removed and 
invaded cells were fixed, stained, and counted as described above. 
 
2.3.10. Data analysis 
 Data were analyzed using Prism 3.0 software and statistical significance was 
determined using InStat 3.0 (GraphPad, San Diego, CA). 
 9
 2.4.  Results 
2.4.1. siRNAs targeted to PARs specifically and effectively cause loss of receptor 
expression 
 Protease-activated receptors are capable of mediating tumor cell responses to a 
variety of extracellular proteases associated with the tumor microenvironment including 
coagulant proteases. Towards defining the relative importance of the individual PARs in 
mediating extracellular protease responses in cancer cells, we generated PAR-specific 
siRNAs to deplete highly invasive breast cancer cells of endogenous PAR proteins. 
Characterization of PAR family members expressed in MDA-MB-231 breast carcinoma 
using reverse-transcriptase polymerase chain reaction (RT-PCR) revealed the presence of 
PAR1 and PAR2 mRNA transcripts (data not shown), consistent with the high-level of 
receptor protein expression previously reported 16,20. We first determined whether siRNAs 
targeted against PAR1 and PAR2 mRNA transcripts were effective at reducing expression of 
these proteins. MDA-MB-231 cells were electroporated with PAR-specific siRNAs and after 
24, 48, and 72 h of siRNA incubation, cell lysates were prepared and the amounts of 
endogenous PAR1 and PAR2 protein remaining were determined by immunoblotting. A 
significant decrease in both PAR1 and PAR2 protein expression was observed after 72 h of 
siRNA incubation (Fig. 2.1A). Small interfering RNAs directed against specific PAR mRNA 
sequences also caused a significant and selective loss of cell surface expression of the 
targeted receptor after 72 h of incubation (Fig. 2.1B). These findings suggest that siRNAs 
targeted to specific PAR mRNA transcripts are effective and selective at causing loss of 
receptor protein.  
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 2.4.2. Loss of PAR expression by siRNAs results in loss of agonist-induced signaling 
We then determined whether siRNA-mediated depletion of specific PAR proteins 
resulted in loss of functional responses by examining agonist-induced phosphoinositide (PI) 
hydrolysis. PAR1 and PAR2 stimulate Gαq-mediated PI hydrolysis primarily through the 
activation of phospholipase C-β 27-28.  In control non-specific siRNA treated cells, thrombin 
and TFLLRNPNDK induced an ~2-fold increase in [3H]IP accumulation following 60 min of 
agonist exposure at 37C (Fig. 2.2.A). In contrast, activated PAR1-stimulated PI hydrolysis 
was markedly impaired in cells depleted of PAR1 by siRNA, whereas signaling by trypsin in 
the same cells was unaffected (Fig. 2.2.A). Similarly, activation of PAR2 with trypsin or 
SLIGKV caused an ~2-fold increase in signaling in control siRNA cells that was virtually 
abolished in cells depleted of PAR2 by siRNA (Fig. 2.2.A). Thrombin signaling remained 
intact in PAR2-deficient cells (Fig. 2.2.A).  These results suggest that depletion of either 
PAR1 or PAR2 protein by siRNA is sufficient to ablate receptor-stimulated signaling to PI 
hydrolysis in highly invasive breast cancer cells.  
We next evaluated whether siRNA-mediated knockdown of PAR proteins affected 
agonist-induced ERK1/2 activation, an important mitogenic signaling pathway.  In cells 
treated with non-specific siRNA, activation of PAR1 with TFLLRNPNDK and of PAR2 with 
SLIGKV caused ERK1/2 activation.  However, PAR1-mediated activated of ERK1/2 was 
abolished in cells depleted of PAR1 protein by siRNA.  In contrast to loss of PAR1 signaling, 
PAR2-specific ERK1/2 activation was unaffected.  Additionally, depleting cells of PAR2 
protein using siRNA resulted in loss of PAR2 agonist-stimulated ERK1/2 activation while 
activation with PAR1-specific agonist peptide TFLLRNPNDK resulted in ERK1/2 activation 
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(Fig. 2.2.B).  Together, these findings strongly suggest that siRNAs targeting specific PAR 
mRNA sequences are effective and selective at depleting highly invasive breast carcinoma 
cells of endogenous PAR protein and inhibiting the corresponding functional responses. 
 
2.4.3. PAR2 is a critical mediator of MDA-MB-231 and BT549 cellular migration and 
invasion 
The functional importance of PAR2 in mediating breast cancer cell migration and 
invasion has not been previously determined.  BT549 cells express endogenous PAR1 and 
PAR2 proteins and PAR-specific siRNAs were effective and selective at reducing 
endogenous receptor function in these cells (data not shown).  Control siRNA treated MDA-
MB-231 and BT549 breast cancer cells exhibited a high degree of basal migration; however, 
the addition of NIH-3T3 fibroblast conditioned medium caused an even greater ~2-fold 
increase in migratory responses.  In contrast, cells lacking PAR2 protein showed a substantial 
~50% inhibition of migration towards conditioned medium comparable to that observed in 
cells depleted of PAR1, whereas basal migration was modestly reduced (Fig. 2.3. A and B). 
These findings suggest that in addition to PAR1,  PAR2 is an important mediator of MDA-
MB-231 and BT549 cell migration induced by NIH-3T3 cell-conditioned medium.  
To determine a role for PAR2 in cellular invasion, we evaluated the ability of MDA-
MB-231 and BT549 cells to migrate and invade towards NIH-3T3 fibroblast-conditioned 
medium.  Knockdown of PAR1 expression by siRNA resulted in significant inhibition of 
breast cancer cell invasion; only ~37% of MDA-MB-231 cells invaded compared to control 
siRNA treated cells (Fig. 2.3 C). Depletion of endogenous PAR1 protein by siRNA in BT549 
cells caused a similar reduction of migration and invasion (Fig. 2.3 D). These findings are 
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consistent with a recent study showing loss of MDA-MB-231 cell invasion towards NIH-3T3 
cell conditioned medium after treatment with PAR1-specific siRNAs 13 and strongly suggest 
that PAR1 is an important mediator of breast cancer cell invasion. Strikingly, in cells 
depleted of PAR2 we also observed a significant loss of MDA-MB-231 and BT549 cell 
invasion, with only ~50% of cells exhibiting an ability to invade through matrigel in response 
to NIH-3T3 cell-conditioned medium (Fig. 2.3 C and D). The simultaneous knockdown of 
both PAR1 and PAR2 proteins also resulted in significant inhibition of MDA-MB-231 and 
BT549 cellular invasion (Fig. 2.3 C and D). These findings are the first to demonstrate a 
critical role for PAR2 in mediating breast cancer cell migration and invasion.  
 
2.4.4. In PAR2-depleted cells, coagulant protease VIIa and Xa-induced migration is 
inhibited 
Tissue factor is expressed in many invasive carcinomas including MDA-MB-231 
cells but not in BT549 breast cancer cells and is critical for the formation and activity of 
upstream coagulant proteases VIIa and Xa. Tissue factor-bound VIIa and Xa can activate 
PAR1 and PAR2, and hence the mechanism by which these upstream coagulant proteases 
contribute to breast cancer cell migration and invasion remains poorly defined. Towards 
understanding the function of factors VIIa and Xa in breast cancer cell migration, we 
assessed the effect of PAR1 versus PAR2 knockdown on coagulant protease-induced breast 
cancer cell migration. We initially examined the ability of MDA-MB-231 cells to migrate in 
response to various concentrations of factor Xa. MDA-MB-231 cells exhibited a high-level 
of migration in the absence of agonist and a sub-maximal 52 nM concentration of factor Xa 
was most effective at stimulating cell migration (Fig. 2.4.A).  The highly migratory MDA-
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MB-231 cells were then electroporated with PAR-specific or non-specific siRNAs and 
allowed to migrate in response to low concentrations of either VIIa, Xa or VIIa and Xa 
together for 3 h at 37C. In cells depleted of PAR1, ~80-90% of cells retained the capacity to 
migrate in response to factors VIIa and/or Xa compared to control siRNA-treated cells (Fig. 
2.4.B). In contrast, cells lacking PAR2 showed a substantially greater inhibition of cell 
migration, with only ~70% of cells exhibiting migratory responses to coagulant proteases 
(Fig. 2.4.B). These findings indicate that the majority of MDA-MB-231 migratory responses 
occur independent of coagulant protease stimulation. However, activation of PAR2 by 
factors VIIa and Xa is capable of enhancing migration of a subpopulation of MDA-MB-231 
breast cancer cells. The MDA-MB-231 cell line is heterogeneous with different 
subpopulations of cells displaying distinct growth and metastatic abilities due to discrete 
variations in gene expression patterns 29. Together, these studies strongly suggest a critical 
function for PAR2 in mediating breast cancer cell migration and invasion and reveal a new 
role for PAR2 as the endogenous receptor for coagulant proteases VIIa and Xa in highly 
invasive breast cancer cells. 
 
2.5. Discussion 
 A link between coagulation and several types of human malignant cancers is well 
established. Tissue factor and coagulant proteases are likely to promote cancer cell invasion 
and metastasis by modulating host vascular cell responses, as well as acting directly on tumor 
cells themselves. Thrombin is the major effector for PAR1, whereas tissue factor-VIIa and 
Xa can activate both PAR1 and PAR2. PAR1 promotes breast cancer cell migration and 
invasion 13-14,21, whereas the function of PAR2 in these processes remains poorly defined. 
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Towards understanding the mechanism by which coagulant proteases and PARs promote 
cancer cell invasion and metastasis, we sought to determine the functional importance of 
PAR2 in breast cancer cells. Depletion of PAR2 protein significantly reduced MDA-MB-231 
and BT549 cell migration and invasion towards NIH-3T3 fibroblast conditioned medium. 
These results strongly suggest that PAR2 is a critical mediator of breast cancer cell migration 
and invasion. Moreover, our findings strongly suggest that PAR2 is the endogenous receptor 
for upstream coagulant proteases VIIa and Xa, whereas thrombin acts mainly at PAR1 in 
breast cancer cells.  
 In addition to PAR1, we show for the first time that PAR2 makes equally important 
contributions to breast cancer cell migration and invasion, as a reduction of PAR2 protein by 
siRNA caused significant decreases in cellular migration and invasion towards NIH-3T3 cell 
conditioned medium comparable to that observed with loss of PAR1. The depletion of PARs 
by siRNA provided an opportunity to rigorously define the role of these receptors in breast 
cancer cell migration and invasion. Previous studies have relied upon the use of blocking 
antibodies, cross desensitization experiments and antagonists that lack PAR selectivity. Our 
siRNA approaches have proven to be highly effective and selective in targeting PAR 
degradation resulting in loss of receptor-specific functional responses in breast cancer cells 
(Figs. 2.1 and 2.2). The transwell migration and invasion assays used in our experiments 
provide a reliable measure of in vitro cellular invasiveness. However, tumor cell metastasis 
involves complex interactions between blood cells, endothelial cells, mesenchymal cells and 
extracellular matrix that cannot be accurately reproduced ex vivo. Thus, future studies are 
necessary to definitively determine the importance of PAR2 in mediating breast cancer cell 
migration and invasion and metastasis in vivo.  
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 Our studies strongly suggest that PAR2 is the endogenous receptor for tissue factor-
VIIa and Xa-mediated invasion in invasive breast cancer cells.  Whether tumor cells or 
surrounding stromal cells generate endogenous factors VIIa and Xa has not been determined. 
Tissue factor-VIIa alone appears to be sufficient to stimulate PAR2 signaling, however, 
tissue factor-VIIa-generated endogenous Xa might also contribute to signaling. In contrast, 
Xa activation of PAR2 occurs independent of tissue factor, indicating that formation of a 
ternary tissue factor-VIIa-Xa complex is not essential for signaling in breast cancer cells. 
Consistent with our findings, PAR2 is the major effector for Xa-elicited responses in 
endothelial cells 30. However, in fibroblasts PAR1 is responsible for virtually all Xa-induced 
signaling responses 9,30. The ability of tissue factor-VIIa and Xa to preferentially cleave and 
activate PAR2, as opposed to PAR1, is likely due to surface expressed cofactors that localize 
and regulate coagulant protease activity and specificity. Indeed, substrate recognition and 
cleavage by coagulant proteases is facilitated by cofactors, which function to properly 
position the substrate scissile bond to the relative membrane-associated protease 31. Clearly, 
tissue factor serves this function for VIIa; however, the cofactor and/or mechanism that 
confers Xa’s preferential recognition and cleavage of PAR2 versus PAR1 in cancer cells 
remains to be determined. The amino-terminal cleavage and activation domain of PAR2 
lacks obvious protease recognition features, besides an adjoining positively charged arginine 
residue essential for serine protease cleavage of the receptor. However, the receptor is not 
cleaved by thrombin, indicating that the scissile bond may confer some specificity. The 
tumor microenvironment is replete with serine proteases as well as zinc-dependent 
metalloproteases, raising the possibility that PAR2 is likely to be cleaved and activated by 
other proteases released by tumor, activated stromal, infiltrating immune or endothelial cells.  
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The mechanism by which PAR2 promotes cancer cell migration and invasion is 
poorly understood. Activated PAR2 stimulates PI hydrolysis and mobilization of Ca2+ in a 
variety of cell types, suggesting that the receptor is capable of coupling to Gq and/or Gi 
signaling pathways 28,32.  However, whether PAR2 regulates important effectors of malignant 
progression such as Ras- and Rho-GTPases in cancer cells has not been determined. In 
addition, activation of PAR2 leads to prolonged increases in ERK1/2 activity, an important 
mitogenic signaling pathway. The early transient increase in ERK1/2 activity induced by 
PAR2 is likely mediated by a G-protein dependent pathway, whereas the slower and more 
persistent ERK1/2 activation involves receptor-interaction with arrestins on endocytic 
vesicles 28,33. Arrestins are multifunctional proteins that act as scaffolds and transducers of 
mitogen-activated protein kinase (MAPK) signaling cascades. Indeed, PAR2-mediated 
ERK1/2 activation and cell migration are significantly inhibited in MDA-MB-231 cells 
lacking arrestins 34. However, whether the spatial and/or temporal activation of ERK1/2 by 
PAR2 is particularly dysregulated in cancer cells has not been determined. Moreover, PAR2 
simulates secretion of angiogenic factors and is capable of regulating the angiogenic process 
22,35.  Thus, PAR2 may facilitate tumor cell invasion and metastasis at least in part by 
contributing to tumor angiogenesis. 
In conclusion, there is increasing evidence for the role of aberrant PAR activation in 
cancer cell invasion and metastasis. PARs appear to be the target of a variety of extracellular 
proteases associated with the tumor microenvironment including serine proteases as well as 
metalloproteases. Previous studies have identified thrombin and metalloproteinase-1 as 
effectors of PAR1 activation on tumor cells 13-14,21.  In this study, we report that PAR2, a 
second protease-activated GPCR, has important functions in mediating cancer cell migration 
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and invasion towards NIH-3T3 fibroblast conditioned medium. The actual proteases 
responsible for PAR2 cleavage and activation present in conditioned medium remains to be 
defined. However, our studies also reveal a new role for PAR2 as the endogenous receptor 
for factors VIIa and Xa signal transduction in breast cancer cells. Whether dysregulated 
PAR2 activation and signaling promotes breast cancer cell migration and invasion will be 
important to determine.  
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Figure 2.1.  PAR-specific siRNAs cause selective and effective loss of receptor 
expression. A.  MDA-MB-231 cells were electroporated with siRNAs targeted to PAR1, 
PAR2 mRNA sequences, or non-specific (ns) control siRNA and after 24, 48 or 72 h cell 
lysates were prepared. Equivalent amounts of protein lysates (~30 µg) were resolved by 
SDS-PAGE, transferred and immunoblotted with anti-PAR1 or anti-PAR2 antibodies.  The 
membrane was stripped and reprobed with anti-actin antibody to control for loading. B.  
MDA-MB-231 cells electroporated with either ns-siRNA and PAR-specific siRNAs were 
incubated with either anti-PAR1 antibody or anti-PAR2 antibody (Ab), fixed and the amount 
of antibody bound to the cell surface was determined by ELISA. The data shown (mean  
S.D.; n=3) are representative of at least three separate experiments. 
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Figure 2.2.  PAR-specific siRNAs cause effective loss of receptor-mediated signaling.  A.  
MDA-MB-231 cells were electroporated with ns-siRNA or PAR-specific siRNAs and after 
72 h of electroporation, cells labeled with myo-[3H]inositol were incubated in the absence or 
presence of PAR1 specific agonists (10 nM α-thrombin or 100 µM TFLLRNPNDK) or 
PAR2 agonists (10 nM trypsin or 100 µM SLIGKV) for 60 min at 37°C and amounts of 
[3H]IPs generated were measured. The data (mean ± S.D.; n=3) are representative of three 
independent experiments. In PAR1 siRNA treated cells, a significant difference (**, p<0.01) 
was observed in trypsin-induced signaling compared to untreated control cells. Similarly, 
thrombin signaling compared to control PAR2-siRNA cells was significantly different (**, 
p<0.01). Statistical analysis was determined using an unpaired Student’s t test.   B.  MDA-
MB-231 cells electroporated with ns-siRNA or PAR specific siRNAs, were serum-deprived 
overnight and then incubated in the absence (-) or presence of 100 µM TFLLRNPNDK (TF) 
or 100 µM SLIGKV (SL) for 30 min at 37C, and immunoblotted for activated ERK1/2 
using anti-phospho-p44/42 MAPK antibodies. Membranes were stripped and reprobed with 
anti-p44/42 MAPK antibody to control for loading.  
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Figure 2.3.  PAR2 is a critical mediator of MDA-MB-231 and BT549 cellular migration 
and invasion.  A and B.  MDA-MB-231 and BT549 cells were electroporated with PAR1-, 
PAR2- specific or non-specific (ns) siRNAs and after 72 h cell migration was assessed using 
transwells coated with collagen IV (MDA-MB-231) or laminin (BT549) containing either 
serum-free medium or conditioned medium prepared from NIH-3T3 fibroblasts as described 
in “Materials and Methods”. The data (mean  S.D.; n=3) shown are the average number of 
cells migrated determined from three different fields and is a representative experiment of at 
least three independent experiments. C and D.  After 72 h of siRNA electroporation, MDA-
MB-231 and BT549 cell migration and invasion towards NIH-3T3 cell conditioned medium 
was examined as described in “Materials and Methods”. The data shown (mean ± S.E.) are 
expressed as the percentage of invaded cells compared to ns-siRNA treated control cells 
performed in duplicate and are the average of three independent experiments.  
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Figure 2.4.  Coagulant protease VIIa and Xa-induced migration is inhibited in PAR2-
depleted cells.  A.  Serum-deprived MDA-MB-231 cells were allowed to migrate in response 
to varying concentrations of factor Xa for 3 h at 37°C and the extent of cellular migration 
was assessed as described in “Materials and Methods”. The data shown (mean ± S.D., n=3) 
are the average number of cells migrated determined from three different fields from one 
experiment is representative of three independent experiments. B.  MDA-MB-231 cells were 
electroporated with PAR-specific or non-specific (ns) siRNAs. After 72 h the ability of 
serum-starved cells to migrate towards 3 nM VIIa, 52 nM Xa or VIIa and Xa together was 
then evaluated. The data (mean ± S.D., n=3) are expressed as the percentage of cells 
migrated compared to VIIa, Xa or VIIa and Xa treated ns-siRNA control cells. The 
difference in the number of PAR2 siRNA treated cells migrating towards VIIa and Xa 
compared to ns-siRNA treated cells was significant (**, p<0.01). Statistical analysis was 
determined using an unpaired Student’s t test. 
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Chapter 3 
Ser336 in the C-terminal Tail of the P2Y1 Receptor Regulates Agonist-promoted 
Internalization 
 
3.1. Abstract 
 We examined the role of a conserved motif, S336RAT339, in the membrane-proximal 
region of the C-terminal tail in agonist-promoted internalization of the P2Y1 receptor in 
MDCK (II) cells. Mutation of Ser336, but not Arg337 or Thr339, to alanine markedly 
increased both the rate and extent of agonist-promoted internalization. Whereas mutation to 
alanine of all serine and threonine residues C-terminal to the SRAT motif in the P2Y1 
receptor abrogated agonist-promoted internalization, further mutation of Ser336 and Thr339 
to alanine resulted in a receptor that internalized similarly to wild type receptors in response 
to agonist. Agonist-promoted [32P]phosphate incorporation into both P2Y1 wild type and 
SRAT  ARAA receptors was similar (~3-fold over basal), indicating that increased 
phosphorylation is not the cause of enhanced internalization. Both P2Y1 wild type and -
ARAA receptors mobilized arrestin3-GFP in an agonist-dependent manner, and 
internalization studies in arrestin 2 & 3 double knockout mouse embryonic fibroblasts 
demonstrated that both receptors required arrestins to undergo agonist-promoted 
internalization. We propose a model in which Ser336 is a critical residue in the transition 
between arrestin-unreceptive (basal) and –receptive (agonist bound) conformational states of 
the P2Y1 receptor. This model predicts that mutation of Ser336 to Ala increases the rate of 
agonist-promoted conversion to its arrestin-receptive conformational state, resulting in 
increased binding of arrestin and enhanced internalization. These studies provide important 
information on the internalization and regulation of the P2Y1 receptor and may increase our 
understanding of a broad range of physiological processes. 
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3.2. Introduction 
Adenine and uridine di- and triphosphates and nucleotide sugars are released 
extracellularly from virtually all cells, where they activate P2-purinergic receptors in an 
autocrine or paracrine manner.  There are two families of P2 receptors, ligand-gated P2X 
receptors and G-protein coupled P2Y receptors, which are broadly distributed and regulate 
myriad physiological processes.  P2Y receptors are further classified into two subfamilies 
based on sequence homology and G-protein coupling. The P2Y1 receptor subfamily, P2Y1, 
P2Y2, P2Y4, P2Y6, and P2Y11, couples to Gαq to stimulate phospholipase C activity and 
activate protein kinase C and mobilize intracellular Ca2+. The P2Y11 receptor additionally 
couples to Gαs to stimulate adenylyl cyclase activity. The P2Y12 receptor family, 
encompassing P2Y12, P2Y13, and P2Y14 receptors, couples to Gαi to inhibit adenylyl cyclase 
and activate potassium channels1-2.  
P2Y1 and P2Y12 receptors are both expressed in platelets and mediate ADP-promoted 
platelet aggregation3-7. P2Y1 activation regulates platelet shape change while activation of 
P2Y12 is necessary for adhesion.  Activation of both of these receptors is required for stable 
formation of platelet aggregates, and inhibition of either receptor by selective antagonists is 
effective in blocking stable platelet aggregation. Clopidogrel, commonly known as Plavix, is 
a P2Y12 receptor antagonist that is the second highest selling prescription drug in the U.S. 
Clopidogrel is a pro-drug that is oxidized by hepatic P450 enzymes to the activate 
metabolite, which irreversibly inhibits ADP-promoted platelet aggregation by binding to the 
P2Y12 receptor and covalently reacting with a cysteine residue in the receptor that is required 
for activity8-9.  ADP-promoted platelet shape change is not affected by clopidogrel, indicating 
that this response is regulated by the P2Y1 receptor4,8,10.  The P2Y1 receptor is a target for 
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antiplatelet compounds as well.  Antagonists MRS21791 and MRS250011 are available for 
non-commercial use, and studies have shown that these antagonists also block ADP-
promoted platelet aggregation11-12; however, to date no P2Y1 receptor antagonist has been 
approved for clinical use. 
Regulation of the ADP response in platelets is the subject of study in a number of 
laboratories. It has been known for some time that ADP released from isolated platelets 
causes them to become refractory to activation by ADP in vitro13. More recently, Gachet and 
co-workers reported that in platelets, the P2Y1 receptor was rapidly desensitized upon 
addition of ADP, while the P2Y12 was refractory to desensitization14 . This same group also 
reported that the P2Y1 receptor was rapidly internalized in both platelets and 1321N1 cells in 
an agonist-dependent manner and resided in the open canalicular system15.  Robson and 
colleagues have shown that deletion of CD39 (eNTPDase-1) results in prolonged bleeding 
times due to desensitization of the platelet P2Y1 receptor, presumably by preventing 
scavenging of ADP by the NTPDase16.  Bordon et al., in a study quantifying the kinetics of 
desensitization, showed that the P2Y1-selective agonist MRS2365 causes very rapid 
desensitization of subsequent ADP-promoted platelet aggregation, with a half-life of 
desensitization of 18 sec11. Thus, it is clear that the desensitization and internalization of the 
P2Y1 receptor is an important means for regulating platelet function. 
Our laboratory has focused on the mechanisms of agonist-promoted internalization of 
the P2Y1 receptor.  We have utilized MDCK (II) epithelial cells, which express an 
endogenous P2Y1 receptor that internalizes in response to ADP challenge with identical 
kinetics and to the same extent as exogenously expressed P2Y1 receptors. These studies have 
suggested a role for the C-terminal tail of P2Y1 in regulating agonist-promoted 
 4
internalization, and have established that two Ser residues, Ser352 and Ser354, are critical for 
agonist-promoted internalization17.  Here, we extend these studies by investigating the 
mechanism and defining critical residues involved in the regulation of agonist-promoted 
P2Y1 internalization.  We show that Ser336, located within a conserved motif in the 
membrane-proximal region of the C-terminal tail, is a critical regulator of agonist-promoted 
internalization.  
 
3.3. Materials and methods 
3.3.1. Reagents and antibodies 
2-(Methylthio) adenosine 5'-diphosphate (ADP) was purchased from Sigma (St. 
Louis, MO).  Monoclonal anti-HA.11 was purchased from Covance (Trenton, New Jersey).  
32P-orthophosphate and I125-conjugated goat anti-mouse were purchased from Perkin Elmer 
(Waltham, Massachusetts).  GFP-tagged arrestin2 and GFP-tagged arrestin3 were generous 
gifts from Dr. JoAnn Trejo (University of California at San Diego). 
 
3.3.2. Cell lines 
MDCK (II) cells were obtained from the Tissue Culture Facility at the University of 
North Carolina at Chapel Hill.  Wildtype and arrestin2/arrestin3-null murine embryonic 
fibroblast (MEFs) cells were generous gifts from Drs. Bryan Roth (University of North 
Carolina at Chapel Hill) and Joann Trejo.  PA317 retroviral packaging cells were kindly 
provided by Dr. John Olson at the UNC Cystic Fibrosis Center.  MDCK (II) cells were 
cultured in 50/50 DMEM/F12 medium supplemented with 5% fetal bovine serum (FBS).  
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1321N1, MEFs, and PA317 cells were maintained in DMEM medium supplemented with 
10% FBS. 
 
 
 
 
3.3.3. Retroviral infections and stable expression of receptor constructs   
Stable expression of P2Y1 wild type and mutant receptors in MDCK (II), 1321N1, 
and MEF cells was achieved by retroviral infection. Receptor constructs cloned into pLXSN 
or pLX-PIH retroviral expression vectors were used to produce virus. Wild type and mutant 
human P2Y1 receptor constructs harbored an amino-terminal HA-epitope tag, 
YPYDVPDYA, following the initiating methionine residue.  Previous studies showed that 
addition of an amino-terminal HA epitope tag does not affect P2Y receptor function18.  
PA317 retroviral packaging cells were seeded at a density of 1 x 106 cells in a 25 cm2 tissue 
culture flask and transfected 24 hours later.  Using the calcium phosphate transfection 
method, each flask was transfected with 14 µg of the receptor construct and 6 µg of VSV-G 
plasmid.  Transfected cells were incubated overnight at 37ºC, the medium was replaced with 
tissue culture medium containing 5 mM sodium butyrate, and cells were incubated for an 
additional 48 hours at 32ºC.  Cell medium containing virus was harvested, filtered, 
supplemented with 8 µg polybrene (Sigma, St. Louis, MO), and added to MDCK (II), 
1321N1, or MEF cells at 70% confluence.  The cells were incubated twice with virus for two 
hours each.  Following infection, the virus-containing medium was replaced with normal cell 
culture medium and cells were incubated at 37ºC for 48 hours.  Retrovirally infected cells 
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were selected in cell medium supplemented with 0.6 µg/mL G418 (Gibco, Bethesda, MD) or 
0.3µg/mL hygromycin (Roche, Indianapolis, IN).  After the death of uninfected control cells, 
MDCK (II) and 1321N1 cells were maintained in normal medium and used for experiments.  
 
3.3.4. Site-directed mutagenesis   
Truncation and point mutations were constructed as previously described (Houston 
thesis).  The P2Y1-334Z and -339Z truncation mutants were constructed using PCR 
amplification with 5 primers containing an EcoRI restriction site and 3 primers containing a 
stop codon after Arg-334 (334Z) and Thr-339 (339Z).  A XhoI restriction site enabled 
cloning into a similarly digested pLXSN. P2Y1-0P (all Ser/Thr residues in the C-terminal tail 
mutated to Ala) and -SRAT-0P (all Ser/Thr residues C-terminal to the SRAT motif mutated 
to Ala) mutant receptors were constructed using long primers up to 60 bases in length that 
overlap by approximately 18 bases.  The sense primer contained a XhoI restriction site and 
the antisense primer contained a BamHI restriction site.  The primers were annealed and 
filled in with the Klenow fragment of DNA polymerase followed by digestion and ligation 
into the P2Y1-339Z truncation mutant containing silent mutations to incorporate the 
necessary restriction sites.  The individual point mutations S336A/T339A, T339A, S336A, 
R337A, and S336D/T339D were constructed by four-primer PCR with HA-P2Y1 in pLXSN 
as template and reverse complementary primers with substitutions at the indicated sites19.  
The amplified products were digested with EcoRI and XhoI restriction enzymes and inserted 
into similarly digested pLXSN, pLX-PIH or pcDNA3.1 vectors.  The resulting plasmids were 
purified using the Invitrogen Concert maxiprep kit (Carlsbad, CA) and sequences were 
confirmed at the UNC DNA Sequencing facility. 
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 3.3.5. Internalization assays   
Cells were seeded at a density of 5 x 104 cells/well in a 24-well plate.  After 48 hours, 
cell medium was replaced with 200 μl DMEM supplemented with 50 mM HEPES (pH 7.4) 
and placed in a water bath at 37ºC for 1 hour.  At the indicated times, 50 µl of 50 M 
2MeSADP (10 µM, final concentration) was added to each well.  To stop the assay, the plate 
was added to an ice-cold water bath and cells were fixed with 4% paraformaldehyde.  
Receptors remaining on the cell surface were labeled with anti-HA.11 monoclonal antibody 
followed by I125-labeled goat-anti mouse secondary antibody.  Cells were then solubilized in 
1 M NaOH overnight, following which cell lysates were collected and counted in a gamma 
counter. 
 
3.3.6. Immunofluorescence confocal microscopy   
Cells were seeded on fibronectin-coated glass coverslips at a density of 5 x 104 
cells/well in a 12-well plate.  After 48 hours, surface receptors were pre-labeled with anti-
HA.11 monoclonal antibody at 4°C for 1 hour.  Cells were stimulated with 2MeSADP (30 
µM) for 30 min, fixed with 4% paraformaldehyde, and permeablized with methanol.  
Receptor internalization was assessed using a goat-anti mouse secondary antibody 
conjugated to Alexa-488 or -594 (Molecular Probes, Carlsbad, CA).  Images were acquired 
using an Olympus Fluoview 300 laser scanning confocal imaging system configured with an 
Olympus IX70 fluorescence microscope fitted with a PlanApo 60X oil objective. Confocal 
XY images sectioned at 0.28 μm were collected sequentially at 800 X 600 resolution with 2X 
optical zoom. 
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 3.3.7. 32P Incorporation assay  
MDCK (II) cells were seeded at a density of 2.5x106 cells/10-cm dish.  After 48 
hours, cells were incubated in phosphate-free DMEM for 1 hour at 37°C and incubated with 
1 mCi of [32P]-orthophosphate for 3 hours at 37°C.  The cells were then challenged with 
either buffer or 10 µM 2MeSADP for 5 min and immediately put on ice.  Cells were lysed in 
RIPA buffer (25 mM Tris-HCl, pH 7.4, 150 mM NaCl, 5 mM EDTA, 1% Triton X-100, 
0.5% Sodium Deoxycholate, 0.1% SDS) supplemented with protease and phosphatase 
inhibitor cocktails.  Receptor protein was immunoprecipitated with anti-HA.11 monoclonal 
antibody and Protein A/G beads, and then solubilized with SDS gel loading buffer. A portion 
(80%) of the sample was electrophoresed on a 10% SDS-PAGE gel, and 32P incorporation 
into the receptor was detected by exposing the fixed and dried gel to X-OMAT film for 6-18 
hrs at -80oC. The remaining 20% was electrophoresed on a 10% SDS PAGE gel and receptor 
protein was detected by western blotting.  
 
3.3.8. Phosphoinositide hydrolysis assay   
1321N1 cells were seeded at a density of 5 x 104 cells/well in a 24-well plate 72 hours 
prior to assay.  Inositol lipids were labeled by adding 2 µCi/ml of [3H]-myo-D-inositol to the 
cells in inositol-free medium 14-20 hours prior to assay. The indicated concentrations of 
2MeSADP in 50 mM LiCl were added to individual wells and incubated for 10 min at 37°C.  
Cells were then lysed in 50 mM formic acid overnight and neutralized with 150 mM 
ammonium hydroxide.  Samples were loaded onto AG10X8 columns and washed 
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sequentially with water and 50 mM ammonium formate.  [3H]Inositol phosphates were eluted 
with 1.2 M ammonium formate/0.1 M formic acid and quantified by scintillation counting. 
 
3.3.9. GFP-tagged arrestin translocation assay   
MDCK (II) cells were nucleofected with HA-tagged wild type or mutant P2Y1 
receptors and GFP-tagged arrestin2 or arrestin 3 using Kit T, program U-023 according to 
manufacturer’s instructions (Lonza, Basel, Switzerland), and then seeded on fibronectin-
coated glass coverslips.  After 48 hours, surface receptors were pre-labeled using anti-HA.11 
monoclonal antibody at 4°C for one hour.  Cells were then stimulated for 5 min at 37°C with 
isoprotenol (30 µM) or 2MeSADP (30 µM).  GFP-arrestin translocation was assessed by 
immunofluorescence confocal microscopy as described above. 
 
3.3.10. Data analysis   
All experiments were performed in triplicate and carried out at least three times.  Data 
were analyzed using Prism 3.0 software and InStat 3.0 (GraphPad, San Diego, CA).  
 
3.4. Results 
3.4.1. The highly conserved S336RAT339 sequence motif is involved in regulation of 
agonist-promoted P2Y1 receptor internalization 
The C-terminal tails of GPCRs commonly contain regulatory signals for agonist-
promoted desensitization and internalization.  Our previous data showed that P2Y1 receptor 
internalization is also regulated through its C-terminal terminal tail.  In particular, two Ser 
residues, Ser352 and Ser354, are phosphorylated upon agonist addition and are critical for 
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receptor internalization (Houston thesis). During the course of these studies, we quantified 
agonist-promoted internalization of the wild type P2Y1 receptor, and P2Y1 receptors lacking 
either the entire C-terminal tail (P2Y1-334Z) or the C-terminal tail immediately past a highly 
conserved S336RAT339 sequence motif (P2Y1-339Z) (Fig. 3.1.A). Wild type P2Y1 receptors 
internalized in response to agonist with a t1/2 ~9.25 min, whereas agonist-promoted 
internalization of the P2Y1-339Z receptor was essentially abolished (Fig. 3.1.B).  
Surprisingly, the P2Y1-334Z receptor internalized both with a similar time course and to the 
same steady-state level as the wild type receptor (Fig. 3.1.B). 
The main difference between the two truncated receptors is the absence of a highly 
conserved sequence motif, S336RAT339, in the 334Z mutant (green bar in Fig. 3.1A).  To 
investigate whether this motif is responsible for the marked differences in internalization of 
the two truncated receptors, we mutated both Ser336 and Thr339 to Ala (ARAA) in the full 
length receptor (Fig. 3.2.A) and quantified changes in cell-surface expression in MDCK (II) 
cells upon agonist addition. Surprisingly, the ARAA mutant receptor displayed enhanced 
agonist-promoted internalization, with faster kinetics (t1/2~ 6.78 min) and a greater extent of 
internalization (Fig. 3.2.B). These data, taken together with data from the truncated receptor, 
suggest that one or more amino acids within the SRAT sequence regulate agonist-promoted 
P2Y1 receptor internalization.  
Both Ser and Thr residues are capable of being phosphorylated (and 
dephosphorylated) during the activation cycle of the receptor. To address the role of agonist-
promoted phosphorylation in P2Y1-R internalization, all potential phosphorylation sites, 
either in the entire C-terminal tail (0P) or only those downstream of the SRAT sequence 
(SRAT-0P), were mutated to alanine residues and agonist-promoted internalization was 
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quantified in MDCK (II) cells. Consistent with our studies showing that Ser352 and Ser354 
are required for agonist-promoted internalization and phosphorylation, agonist-promoted 
internalization of the SRAT-0P receptor was abolished, even after 60 min of agonist 
stimulation (Fig. 3.2.B). In contrast, the P2Y1-0P receptor internalized in response to agonist 
with kinetics similar to wild-type receptor (Fig. 3.2.B). To ensure that phosphorylation of 
other residues in the receptor was not occurring, we also quantified agonist-promoted 
internalization of the P2Y1 receptor in which all cytoplasmic Ser and Thr residues, including 
those in the three intracellular loops, were mutated to Ala (P2Y1-Pan0P). In response to 
agonist, the Pan0P receptor internalized with kinetics identical to the P2Y1-0P receptor (data 
not shown). These data suggest that phosphorylation is not required for agonist-promoted 
internalization of the P2Y1 receptor. The contradictory data with P2Y1-SRAT-0P and P2Y1-
0P receptors suggest a complex regulation of agonist-promoted P2Y1 receptor internalization 
involving the SRAT sequence and agonist-promoted phosphorylation of the C-terminal tail. 
To test if potential phosphorylation of the SRAT sequence plays any role in agonist-
promoted internalization, we generated a phospho-mimetic DRAD mutant receptor that 
theoretically imitates a receptor that is permanently phosphorylated, and following 
expression in MDCK (II) cells, assessed agonist-promoted internalization.  Even after 60 min 
of agonist stimulation, the DRAD receptor failed to internalize (Fig. 3.3..B). 
 
3.4.2. Ser336 is the key residue regulating agonist-induced P2Y1 internalization 
To address which residues within the SRAT sequence regulate agonist-stimulated 
P2Y1 receptor internalization, we mutated Ser336, Arg337, and Thr339 individually in the 
context of the full length receptor (Fig. 3.3.A) and quantified surface expression of wildtype 
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or mutant receptors in MDCK (II) cells following activation with 10 µM 2MeSADP.  The 
kinetics and extent of internalization of both the SRAA and SAAT mutant receptors were 
identical to wild type, whereas those of the ARAT mutant receptor were identical to the 
ARAA receptor (Fig. 3.3.B). These results implicate Ser336 as the critical residue within this 
sequence for regulation of internalization.   
 
3.4.3. Ser336 regulates agonist-induced P2Y1 internalization in 1321N1 human 
astrocytoma cells 
In our quest to find a cell line in which to investigate agonist-promoted internalization 
of the P2Y1 receptor, we observed that exogenously expressed P2Y1 receptors did not 
internalize in most common cell lines tested (e.g. HEK293, HeLa, C6 glioma, and 1321N1 
astrocytoma cells; data not shown), whereas other P2Y receptors, i.e. P2Y2 and P2Y4 
receptors, did undergo agonist-promoted internalization, indicating that the inability to 
observe agonist-promoted P2Y1 receptor internalization was not due to a defect in the 
endocytic machinery of the cells. In contrast, exogenously expressed P2Y1 receptors in 
MDCK cells internalized in response to agonist with identical kinetics and to the same extent 
as endogenously expressed P2Y1 receptors (Houston thesis), indicating that the P2Y1 
receptor internalization may be differentially regulated depending on its cellular context. 
To test whether the SRAT sequence has a role in the inability of the receptor to 
undergo internalization in these cell lines, we generated 1321N1 cells stably expressing HA-
tagged P2Y1 wild type, -ARAA, -SRAA, or -ARAT receptors and assessed agonist-promoted 
internalization. Consistent with our past observations, the wild type P2Y1 receptor did not 
internalize after 60 min of agonist stimulation (Fig. 3.4.A).  In contrast, after 60 min of 
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agonist-stimulation, ARAA and ARAT mutant receptors internalize with a  t1/2 ~19.0 min, 
whereas the SRAA mutant receptor did not internalize (Fig. 3.4.A). Internalization data also 
was confirmed by immunofluorescence confocal microscopy (Fig. 3.4.B). These data support 
our findings that Ser336 is a critical regulator of P2Y1 internalization, although the reasons 
for the absence of agonist-promoted internalization of the wild type P2Y1 receptor in 1321N1 
cells remain unknown. 
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 3.4.4. Phosphorylation of P2Y1 receptor SRAT mutants 
One explanation for the increased internalization of the SRAT mutants is that they are 
more heavily phosphorylated in response to agonist. To directly assess agonist-induced 32P 
incorporation of wild type and SRAT mutants, MDCK (II) cells expressing various mutant 
receptor constructs were labeled with [32P]orthophosphate and both basal and agonist-
promoted [32P]phosphate incorporation into each receptor was determined.  Both P2Y1 wild 
type and -ARAA receptors incorporated similar levels of basal and agonist-promoted 
[32P]phosphate, with phosphorylation increasing ~3-fold over basal (Fig. 3.5.A). These data 
suggest that the increased internalization observed with P2Y1-ARAA (and –ARAT) receptors 
is not due to increased agonist-promoted phosphorylation. In contrast, P2Y1-SRAT-0P, CT-
0P and –Pan-0P receptors did not show increased agonist-dependent phosphorylation (Fig. 
3.5.B and data not shown), suggesting that Ser336 and Thr339 are not phosphorylated in an 
agonist-dependent manner. P2Y1-DRAD receptors, which do not undergo agonist-promoted 
internalization, appeared highly phosphorylated in the basal state, and phosphorylation 
increased ~3-fold upon agonist addition. These data indicate that phosphorylation by itself is 
not sufficient for internalization.  
Lastly, we examined agonist-promoted phosphorylation of the P2Y1 receptor in 
1321N1 human astrocytoma cells. As seen in the right panel of Fig. 3.5.A, the P2Y1 receptor, 
which does not internalize in these cells, is phosphorylated in an agonist-dependent manner.  
These data further confirm that P2Y1 receptor phosphorylation is not sufficient for agonist-
promoted internalization. 
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 3.4.5. P2Y1 mutant receptors are functional 
One possibility to explain the lack of internalization of some of the mutant receptors 
is that these receptors are inactive and incapable of coupling to G proteins. To investigate this 
possibility, we examined the signaling properties of the mutant receptors by quantifying 
inositol lipid hydrolysis in 1321N1 cells.  1321N1 cells are the cell line of choice when 
quantifying P2Y receptor activation, since they lack endogenous P2Y receptors.  As shown 
in Fig 3.5.B, all of the P2Y receptor mutants examined displayed robust agonist-promoted 
inositol phosphate accumulation. Moreover, the EC50 values of 2MeSADP for wild type and 
mutant receptors were comparable, indicating that the mutations have no effect on coupling 
to Gq.  
 
3.4.6. Translocation of GFP-tagged arrestin2 and arrestin3 following P2Y1 receptor 
activation 
Addition of agonists to a broad range of GPCRs results in translocation of co-
expressed GFP-tagged arrestins to the plasma membrane20-22, which is often used as a 
measure of receptor-arrestin interaction.  To address the role of the SRAT sequence in P2Y1 
receptor-mediated arrestin activation, agonist-promoted GFP-tagged arrestin mobilization 
was determined in MDCK (II) cells expressing wild type and mutant receptor constructs. 
MDCK (II) cells were co-nucleofected with HA-β2AR (control) or with P2Y receptor 
mutants, together with either GFP-arrestin2 or GFP-arrestin3, and seeded on glass coverslips 
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for immunoflorescence microscopy.  Surface receptors were pre-labeled and stimulated for 5 
min with either 30 µM isoprotenol (β2AR) or 2MeSADP (P2Y1-R). 
Distribution of the β2AR went from primarily plasma membrane-bound to punctate, 
internalized vesicles and GFP-arrestin3 localization changed from diffuse cytoplasmic 
staining under control conditions to punctate staining following agonist treatment.  This 
GFP-arrestin mobilization suggests that GFP-arrestin3 is translocated from the cytoplasm to 
the activated β2AR and functions in receptor internalization.  Consistent with literature 
demonstrating no role for arrestin2 in β2AR internalization23-24, GFP-arrestin2 did not 
translocate despite receptor internalization (data not shown). Following 5 min of stimulation 
with 2MeSADP (30 µM), both GFP-arrestin2 (Fig. 3.6.A, panel E) and GFP-arrestin3 (Fig. 
3.6.B, panel E) translocated and colocalized with internalized P2Y1 receptors, as indicated by 
the yellow punctate staining in Figs. 3.6.A and 3.6.B, panel F.  Colocalization of the P2Y1 
receptor with GFP-arrestin3 was more robust than with GFP-arrestin2, which was consistent 
with published studies on the roles of both arrestin2 and arrestin3 in P2Y1 internalization25. 
To test the function of the SRAT sequence on GFP-tagged arrestin3 activation and 
translocation in MDCK (II) cells, we co-expressed GFP-arrestin3 with the P2Y1-ARAT (Fig. 
3.7.A), -0P (Fig. 3.7.E), -334Z (Fig. 3.7.I), and -SRAT-0P (Fig. 3.7.M) receptors.  Upon 
agonist stimulation of the P2Y1-ARAT and P2Y1-0P receptors, GFP-tagged arrestin3 
translocated to internalized puncta together with the receptor (Fig. 3.7, panels C and G), 
suggesting that mutation of the SRAT sequence does not inhibit P2Y1 receptor-mediated 
arrestin translocation.  Interestingly, these data also suggest that translocation of GFP-
arrestin3 occurs independent of carboxyl-tail phosphorylation, provided that Ser336 is 
mutated to Ala.  GFP-arrestin2 translocation was also observed following agonist 
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stimulation, although always to a lesser extent than GFP-arrestin3 (data not shown). In 
contrast, agonist addition to cells expressing the P2Y1 SRAT-0P receptor neither promoted 
internalization (Fig. 3.7.N) nor resulted in translocation of GFP-arrestin3 (Fig. 3.77) or GFP-
arrestin2 (data not shown).  Interestingly, agonist stimulation of the P2Y1-334Z receptor 
leads to internalization (Fig. 3.7.J), but not GFP-arrestin3 translocation (Fig. 3.7.K).  These 
data suggest that in the absence of the carboxyl-terminus, P2Y1 internalization is through an 
alternate, arrestin-independent mode of internalization. 
 
3.4.7. P2Y1 wild type and SRAT receptors fail to internalize in arrestin2,3 knock-out 
murine embryonic fibroblast cells 
Although our results demonstrate that agonist activation of the P2Y1 receptor causes 
the translocation of GFP-arrestins and internalization of the receptor, they do not address 
whether the arrestins are required for receptor internalization. To confirm whether arrestins 
were necessary for receptor internalization, we expressed P2Y1 wild type, -ARAT, and -
SRAT-0P receptors in both normal mouse embryonic fibroblasts (MEFs) and 
arrestin2/arrestin3-knockout MEFs and quantified agonist-promoted internalization in the 
two cell lines.  Consistent with our data in MDCK (II) cells, following 30 min of agonist 
treatment both P2Y1 wild type and -ARAT receptors internalized in normal MEFs, whereas 
P2Y1-SRAT-0P receptor internalization was not observed (Fig. 3.8.A). In arrestin2,3 
knockout cells, however, agonist-promoted P2Y1 wild type and -ARAT receptor 
internalization was completely blocked (Fig. 3.8.B). These data indicate that arrestins are 
required for P2Y1 receptor internalization and that mutation of the SRAT sequence does not 
prevent P2Y1 receptor-mediated arrestin translocation. 
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3.5. Discussion 
 Previous work from our laboratory examining the mechanisms involved in agonist-
promoted internalization of the P2Y1 receptor established that two Ser residues, Ser352 and 
Ser354 are phosphorylated upon agonist addition and are the primary residues that mediate 
receptor internalization in MDCK (II) cells.  In the course of this study, we observed that 
receptors truncated after Thr339 (P2Y1-339Z) did not undergo agonist-promoted 
internalization, whereas receptors missing an additional five amino acids (P2Y1-334Z) 
internalized similarly to wild type receptors (Fig. 3.1.B).  These data focused attention on the 
apparent importance of a conserved sequence motif, S336RAT339, in regulating agonist-
promoted internalization of the receptor.  We show here that mutation of Ser336, but not 
Arg337 or Thr339 within this motif alters both the rate and extent of agonist-promoted 
internalization of the P2Y1 receptor (Figs. 3.2.B, 3.3.B, data not shown).  Mutation of Ser336 
to Ala increased internalization, whereas mutation of both Ser336 and Thr339 to Asp ablated 
internalization (Fig. 3.2.B).  Additionally, whereas wild type P2Y1 receptors do not 
internalize in 1321N1 astrocytoma cells, mutation of both Ser336 to Ala imparted the ability 
of the P2Y1 receptor to undergo agonist-promoted internalization in these cells (Fig. 3.4).  
Mutation of Ser336 does not interfere with arrestin binding to agonist-bound receptors, and 
internalization of both P2Y1-ARAT and P2Y1-0P receptors is arrestin-dependent (Fig. 3.8).  
Taken together, our data strongly support a role of Ser336 as a key residue in determining the 
kinetics and extent of internalization of the P2Y1 receptor. 
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 Based on our data, we propose that P2Y1 internalization is a bi-phasic process.  In a 
basal state, the carboxyl-tail of the P2Y1 receptor interacts with the intracellular body of the 
receptor through the SRAT sequence.  Following agonist binding, residues Ser352 and 
Ser354 are phosphorylated, resulting in the SRAT sequence being released from the body of 
the receptor.  Arrestins can then bind to the receptor body to facilitate internalization (Fig. 
3.9).   
 Based on our model, the P2Y1-339Z mutant does not internalize (Fig. 1B) because it 
is lacking agonist-promoted phosphorylation at Ser352 and Ser354.  Thus, the SRAT 
sequence is not released from the receptor body to allow arrestin binding and subsequent 
internalization.  We will address the mode of internalization of the P2Y1-334Z mutant 
according to the model later in the discussion.  When Ser336 is mutated to Ala, as in the case 
of P2Y1-ARAA and –ARAT receptors, we believe that interaction between the carboxyl-tail 
(via the SRAT sequence) and the body of the receptor is decreased, leading to an increase in 
internalization (Fig 3.3.B). 
Curiously, we do not see agonist-promoted P2Y1 receptor internalization in several 
common cell lines, including HEK293, CHO, C6, and 1321N1 astrocytoma cells.  In 
HEK293 cells, which endogenously express the P2Y1 receptor, neither the native nor 
exogenously expressed receptors internalize in response to agonist (data not shown).  The 
reason for the lack of internalization is not currently understood, although we do observe 
agonist-promoted phosphorylation and conclude that a defect in phosphorylation is probably 
not involved (Fig. 3.5). However, the P2Y1- ARAA and –ARAT mutant receptors did 
internalize following agonist treatment. These data support our model that Ser336 is a critical 
regulator of P2Y1 internalization (Fig. 4).   
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Phosphorylation of GPCRs is a key post-translational modification that occurs upon 
activation of receptors by agonist and precedes internalization of the receptor.  To examine 
the role of phosphorylation in agonist-promoted P2Y1 receptor internalization in MDCK (II) 
cells, we quantified internalization of mutant receptors.  Because serines and threonines are 
potential phosphorylation sites, we also examined the internalization of mutant receptors that 
are lacking all potential phosphorylation sites in the absence or presence of the SRAT 
sequence.  We find that the SRAT-0P mutant receptor does not internalize following agonist 
treatment, suggesting that carboxyl-tail phosphorylation downstream of the SRAT sequence 
is required (Fig. 3.2.B).  In the context of our model, SRAT-0P internalization is inhibited 
because Ser352 and Ser354 are not phosphorylated and the SRAT sequence is not released 
from the body of the receptor to allow arrestin biding and subsequent internalization. 
We also find that the P2Y1-0P receptor, which lacks all potential carboxyl-terminal 
phosphorylation sites, internalizes comparably to the wild type receptor (Fig. 3.2.B).  These 
data can be explained by our model as well.  Although there is no agonist-promoted 
phosphorylation of the mutant receptor (Fig. 3.5.A), the SRAT sequence is not interacting 
with the body of the receptor due to the mutations of the Ser and Thr of the SRAT sequence 
to Ala.  Consequently, arrestin can freely bind to the receptor following treatment to facilitate 
internalization.   
The possibility that phosphorylation of either Ser336 or Thr339 was involved in the 
increased internalization of the SRAT mutants was not supported by 32P phosphorylation 
experiments.  Paradoxically, we observed hyper basal phosphorylation of the P2Y1-DRAD 
receptor, but equal fold increase in phosphorylation following agonist treatment compared to 
the wild type receptor (Fig. 3.5.A).  Based on the model, we believe that the hyper 
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phosphorylation causes the receptor c-tail to more tightly interact with the body of the 
receptor and that we do not observe P2Y1-DRAD internalization following agonist treatment 
because Ser352 and Ser354 phosphorylation is not sufficient to release the DRAD sequence 
from the body of the receptor. 
Lastly, we show that activation of the P2Y1 receptor mobilizes GFP-arrestin3, and to 
a lesser extent, GFP-arrestin2 in a SRAT and carboxyl-tail phosphorylation-independent 
manner (Figs. 3.6 and 3.7).  Studies using the P2Y1-334Z receptor, which lacks the entire 
carboxyl-terminal tail, reveal that the tail is required for arrestin mobilization.  This mutant 
internalizes upon agonist treatment, but cannot mobilize GFP-arrestin, suggesting an arrestin-
independent mechanism of internalization (Fig. 3.7 panels I, J, K, and L).  Thus, our model is 
not applicable to this mutant. 
Our internalization experiments in arrestin2/arrestin3 null MEFs confirm published 
observations that arrestins are required for P2Y1 internalization (Fig. 3.8).  Other GPCRs, 
such as δ-opioid and receptors, have been shown to activate arrestins independent of 
phosphorylation26.  For several GPCRs, including the CXCR4 receptor, phosphorylation of 
the third intracellular loop is also a site of regulation for agonist-promoted internalization27.  
Further studies should focus on the third intracellular loop for P2Y1 to determine the region 
and/or residues required for arrestin interactions. 
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Fig. 3.1.  Importance of the SRAT sequence in P2Y1 regulation is illustrated by 
carboxyl-tail truncation mutants.  A. The SRAT motif (green bar) in the P2Y1 receptor C-
terminal tail is evolutionarily conserved.  Arrows indicate the last amino acids of the P2Y1-
334Z and -339Z truncation mutants, and the two critical residues that are phosphorylated in 
response to agonist and mediate internalization are denoted by an *.  B. Serum-deprived 
MDCK (II) cells stably expressing P2Y1 wildtype, -334Z or -339Z receptors were stimulated 
with 10µM 2MeSADP for the indicated times.  The levels of receptors remaining at the cell 
surface were quantified as described in “Materials and methods” and reported as remaining 
cell surface expression compared to control (0 min) cells.   
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Fig. 3.2.  SRAT sequence regulates agonist-promoted P2Y1 internalization.  A. Ser and 
Thr residues in the C-terminal tail of the wild type receptor are highlighted in red, and 
residues mutated to Ala are highlighted in green.  B. Serum-starved MDCK (II) cells stably 
expressing P2Y1 wild type, -ARAA, -SRAT-0P, -0P, or -DRAD receptors were stimulated 
with 10µM 2MeSADP for the indicated times. The levels of receptors remaining at the cell 
surface were quantified as described in “Materials and methods” and reported as remaining 
cell surface expression compared to control (0 min) cells. 
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Fig. 3.3.  Ser336 is the critical residue in regulation of agonist-promoted P2Y1 receptor 
internalization.  A. SRAT mutants (green) are shown. B. Serum-starved MDCK (II) cells 
stably expressing P2Y1 wildtype, -SRAT, -ARAT, and -SRAA receptors were stimulated 
with 10µM 2MeSADP for the indicated times. The levels of receptors remaining at the cell 
surface were quantified as described in “Materials and ,methods” and reported as remaining 
cell surface expression compared to control (0 min) cells. 
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Fig. 3.4.  Mutation of Ser336 to Ala allows agonist-induced P2Y1 internalization in 
1321N1 cells.  A.  Serum-deprived 1321N1 cells stably expressing P2Y1 wildtype, -ARAA, -
SRAA, and -ARAT mutant receptors were treated with 10µM 2MeSADP for the indicated 
times. The levels of receptors remaining at the cell surface were quantified as described in 
“Materials and methods” and reported as remaining cell surface expression compared to 
control (0 min) cells.  B.  Confocal images of 1321N1 cells showing location of the indicated 
P2Y1 receptors in the basal state and following agonist stimulation. Surface HA-tagged 
receptors were prelabeled with anti-HA.11 monoclonal antibody at 4ºC for 60 min, followed 
by agonist-stimulation for 30 min at 37ºC.  Cells were then fixed with 4% PFA, 
permeabilized with methanol, and incubated with goat anti-mouse secondary antibody. 
WT ARAA SRAA ARAT 
control 
30 min 
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Fig. 3.5.  [32P]Phosphate incorporation into P2Y1 wild type and SRAT mutant 
receptors.  A. MDCK (II) and 1321N1 cells expressing P2Y1 wild type and SRAT mutant 
receptors were incubated with 1 mCi [32P]phosphate to label the ATP pool. After 3 hrs, cells 
were either not challenged or incubated with 30 M ADP for 5 min, the HA-tagged receptors 
were immunoprecipitated, and the eluted samples were split 20/80 for Western 
blotting/autoradiography. Top panel, Western blot. Middle panel, autoradiograph from 2 hr 
exposure. Bottom panel, autoradiograph from 6 hr exposure (DRAD lane removed).   B.  
1321N1 cells expressing P2Y1 wild type and SRAT mutant receptors were labeled with 2 
µCi/ml of [3H]-inositiol and stimulated with the indicated concentrations of 2MeSADP for 
10 min at 37°C in the presence of 50 mM LiCl.  [3H]Inositol phosphate accumulation was 
quantified as described in Materials and methods.  Data courtesy of Aidong Qi, Ph.D. 
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Fig. 3.6.  Arrestins are mobilized following P2Y1 receptor activation.  MDCK (II) cells 
were co-nucleofected with HA- P2Y1 receptor and either arrestin2-GFP (A) or arrestin3-GFP 
(B) and after 2 days in culture were either left untreated (control) or treated for 5 min with 10 
M 2MeSADP. Cells were processed and imaged by confocal microscopy as described in the 
legend to Fig. 4. 
merge merge F. merge merge F. C. C. 
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Fig. 3.7.  Agonist-promoted mobilization of Arr3-GFP following activation of P2Y1 
receptors is SRAT- and phosphorylation-independent.  MDCK (II) cells were co-
nucleofected with GFP-tagged arrestin 3 and HA-tagged P2Y1-ARAT (A), P2Y1-0P (E), 
P2Y1-334 (I), or P2Y1-SRAT-0P (M) receptors as described in “Materials and methods.”  
Cells were processed and imaged by confocal microscopy as described in the legend to Fig. 
3.4.  
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Fig. 3.8.  P2Y1 wildtype and ARAA receptors fail to internalize in arrestin knock-out 
MEFs.  Serum-deprived wildtype (A) and arrestin knock-out (B) MEF cell lines stably 
expressing P2Y1 wildtype, ARAT, SRAT-0P or 0P receptors were stimulated with 
2MeSADP (10µM) for 30 min.  Internalization was quantified as described in “Materials and 
methods.”   
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Fig. 3.9.  Proposed model of P2Y1 receptor internalization.  In the absence of agonist, the 
C-terminal tail, through interactions of Ser336 with other parts of the receptor, structurally 
inhibits the binding of arrestin to the receptor.  Upon ligand activation, Ser352 and Ser354 
are phosphorylated, causing a conformational change and release of the tail from the body of 
the receptor.  Activated arrestin is then able to bind to an intracellular loop of the receptor to 
facilitate internalization. See text for details 
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Chapter 4 
Conclusions and Future Directions 
 G protein-coupled receptors (GPCRs) are therapeutic targets for a broad range of 
human disease, including cardiovascular disease, gastrointestinal disease, and cancer.  Thus, 
understanding how these receptors function in both normal and pathophyisological 
conditions, as well as how they are regulated, is critical in understanding the mechanisms of 
disease and how to treat them effectively.   
The work presented in this dissertation involves two similar projects focused on 
signaling and regulation of GPCRs involved in cancer and/or cardiovascular physiology. The 
first project demonstrated the requirement for Protease-activated receptor-2 (PAR2) in 
coagulant protease-mediated signaling, migration, and invasion of breast carcinoma cells by 
utilizing siRNA techniques to specifically inhibit expression of either PAR1 or PAR2. The 
second project investigated the mechanisms by which another receptor important in the 
cardiovascular system, the P2Y1 receptor, is internalized following agonist challenge. 
Receptor internalization is important in regulating GPCR signal termination, but the 
mechanisms involved in internalization of the P2Y1 receptor had not been elucidated. These 
studies demonstrated that P2Y1 internalization occurs through a novel mechanism by which a 
single amino acid, Ser336, within a conserved C-terminal motif, determines the rate and 
extent of agonist-promoted internalization of the P2Y1 receptor. 
 
4.1. Protease-activated receptors and coagulant proteases in cancer progression 
 In Chapter 2, we used siRNA to specifically deplete two cancer cell lines, MDA-MB-
231 and BT549, of natively expressed PAR1 and PAR2, and showed that both PAR1 and 
PAR2 are critical mediators of cellular migration and invasion.  We also showed that 
depleting cells of PAR2, but not PAR1, inhibits coagulant protease VIIa and Xa-induced 
migration of breast carcinoma cells. 
 In the tumor microenvironment, activation of the coagulation cascade is a hallmark of 
cancer and cell surface tissue factor (TF) is the major stimulant of the coagulation cascade.  
TF forms a catalytic enzyme complex with coagulant protease factors VIIa and Xa to trigger 
coagulation.  Aberrant expression of PAR1 and PAR2, both of which can be activated by the 
TF-VIIa-Xa complex, has been correlated with the invasive and metastatic properties of 
tumor cells1.  While we have been able to show that PAR2 is required for VIIa and Xa-
induced migration of breast cancer cells in vitro, it is imperative to show that the same is true 
in vivo for potential therapeutic value.  
  Indeed, Versetteg et. al, 2008 addressed spontaneous mammary tumor development 
in PAR1-/- and PAR2-/- mice using the mouse model of polyoma middle T (PyMT) oncogene 
expression under the control of the mouse mammary tumor virus (MMTV) promoter to 
recapitulate important aspects of human breast cancer pathology. Their results demonstrate a 
critical role for PAR2, but not PAR1, in spontaneous breast cancer development and 
metastasis2, supporting our findings. What was most interesting about this study, however, 
was that the progression from adenoma formation to adenocarcinoma was not prevented in 
PAR2-/- mice, but was only delayed, suggesting that PAR2 signaling does lead to tumor cell 
angiogenesis.  It is uncertain whether the delayed angiogenic switch is due to deceased tumor 
growth, and while PAR2 signaling has been implicated in tumor cell proliferation and 
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apoptosis as well as migration 1,3-5, it is unlikey that PAR2 is a major contributor to tumor 
cell proliferation since tumor growth was normal once angiogenesis occurred.  Thus, direct 
inhibition of PAR2 alone may not be sufficient for therapeutic treatment, but may be more 
effective when used in conjunction with other therapies by delaying the progression of tumor 
cell angiogenesis. 
 
4.2. Regulation of P2Y1 internalization 
 In Chapter 3, we showed that the Ser336 residue within an evolutionarily conserved 
motif, S336RAT339, regulates agonist-promoted internalization of the P2Y1 receptor in MDCK 
(II) cells, a canine epithelial cell line.  Our data are consistent with a model in which Ser336 
interacts with unknown residues in the intracellular loops of the main body of the receptor in 
the basal state, and that this interaction puts the receptor in an arrestin-unreceptive state. 
Following agonist treatment, the C-terminal tail is phosphorylated at two Ser residues, 
Ser352 and Ser354, which weakens the interaction of the C-tail with the receptor and helps to 
convert the receptor into an arrestin-receptive state, allowing for interaction with arrestins to 
facilitate internalization.  We also show that while arrestins are required for agonist-
promoted internalization, an intact SRAT motif is not required for arrestin interaction.  
Interestingly, the P2Y1 receptor is also unlike canonical G protein-coupled receptors in that it 
does not require agonist-promoted C-terminal tail phosphorylation in order to internalize 
provided that Ser336 has been mutated to Ala.  Other GPCRs, such as δ-opioid and 
lutropin/choriogonadotropin receptors have been shown to activate arrestins independent of 
phosphorylation6-7.   
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 Based on studies conducted mainly with the β2-AR, the general dogma for GPCR 
internalization is that upon ligand activation, the C-termini of GPCRs are phosphorylated, 
which increases their affinity for arrestin. Once bound, arrestin promotes both desensitization 
and internalization. For several GPCRs, including the CXCR4 and luteinizing 
hormone/choriogonadotropin receptors, phosphorylation of the third intracellular loop is also 
a site of regulation for agonist-promoted internalization8-9. However, our studies with a 
mutant P2Y1 receptor in which all Ser and Thr residues in intracellular domains (P2Y1-
Pan0P) were mutated to Ala demonstrated that the receptor internalized similarly as P2Y1-
0P, in which only the Ser/Thr residues in the C-terminal tail were mutated to Ala, in response 
to agonist challenge. These data thus ruled out the possibility of intracellular phosphorylation 
sites mediating arrestin binding to the P2Y1 receptor. 
 Our laboratory previously demonstrated that P2Y1 receptor internalization is 
differentially regulated based on which cells it is expressed.  For example, the P2Y1 receptor 
does not internalize following the addition of agonist in human embryonic kidney epithelial 
HEK293 cells, HeLa cervical carcinoma cells, or in 1321N1 astrocytoma cell lines.  We do 
know that the lack of agonist-promoted P2Y1 internalization in 1321N1 cells is not due to a 
defect in the endocytic machinery of the cell line, since P2Y2 and P2Y4 receptors internalize 
upon agonist internalization.  We do know that in 1321N1 cells, the P2Y1 receptor undergoes 
agonist-promoted phosphorylation (Fig. 3.5A), and recent preliminary data suggest that 
1321N1 cells express both arrestin2 and arrestin3. Thus, the absence of agonist-promoted 
internalization of the P2Y1 receptor in 1321N1 cells does not appear to be due to lack of 
phosphorylation or expression of arrestins. Thus, future investigation into the mechanisms 
involved in the different internalization properties observed in different cell lines may 
 4
provide valuable insight into the regulation of various processes regulated by P2Y1 receptor 
signaling, including ion and water transport across epithelia, smooth muscle relaxation, and 
platelet activation.  Future preliminary experiments may include screening the different cell 
lines for the expression (or lack thereof) of various endocytic adaptor proteins.  
 The work in Chapter 3 shows that arrestins are required for agonist-promoted P2Y1 
receptor internalization, but one aspect of the model remains untested: that the Ser336A 
mutation leads to an increase in both the rate and extent of arrestin binding upon addition of 
agonist. Experiments quantifying the receptor-arrestin interaction would allow a direct 
correlation between internalization and arrestin binding, and would help to test directly the 
model we have proposed. Bioluminescence Resonance Energy Transfer (BRET) is a 
technique that is capable of measuring both the magnitude and kinetics of arrestin binding; 
fusion of Renilla luciferase (Rluc) to the end of P2Y1 wild type, -ARAT, and -0P receptors 
and co-expression of these receptors with arrestin3 fused to Yellow Fluorescent Protein 
(YFP) would, upon addition of luciferase substrate and receptor agonists, generate resonance 
transfer of light from luciferase to YFP provided that the two proteins interact. This approach 
will provide both kinetic data on how fast arrestins bind and to what level after addition of 
agonists, and these data would help to test our model that Ser-336 is a key gateway between 
receptor-unreceptive and –receptive states. Such experiments are currently in progress. 
 P2Y receptor signaling is important for platelet shape change and adhesion to mediate 
normal aggregation upon blood vessel injury.  While clopidogrel, a P2Y12 receptor-selective 
antagonist is commercially available and highly prescribed, no P2Y1 receptor-selective 
therapies are currently available for therapeutic use.  In fact, very little published information 
regarding P2Y1 receptor regulation in platelets exists, despite its relevance as a target for 
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antiplatelet compounds.  It has been recently shown that the P2Y1 receptor rapidly 
desensitizes in platelets in response to the P2Y1-selective agonist MRS 236510.  Other reports 
have suggested that the P2Y1 receptor is rapidly phosphorylated and internalized in human 
platelets and astrocytoma cells11, although the latter results conflict with our own data.   
Studying the regulation of P2Y1 receptor internalization in platelets is difficult due to 
the lack of a nucleus.  Thus, we are unable express exogenous mutant receptors to study the 
mechanisms internalization in platelets directly.  The MDCK cell line was chosen to study 
internalization based on two criteria:  1) the P2Y1 receptor is natively expressed and 2) intact 
radioligand binding assays show that exogenously expressed receptors internalize at rates 
comparable to the native receptor.  Further studies directly assessing the regulation of the 
P2Y1 receptor in platelets is necessary in order to achieve a P2Y1-specific antiplatelet 
compound. 
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